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Summary 
This report is the seventh national report on the performance of the National Cervical 
Screening Program in Australia. Cervical screening services are provided as part of 
mainstream health services with general practitioners performing the great majority of Pap 
smears. The program is funded by the Australian Government and the state and territory 
governments. 
This report presents statistics on the national performance monitoring indicators for the 
program. These were developed by the National Advisory Committee to the program; in 
2004 this committee was replaced by the Australian Screening Advisory Committee.  
Overview 
The major goals of the Program are to reduce incidence and mortality through screening to 
detect abnormalities of the cervix early so that medical intervention can avert the possible 
progression to cervical cancer. 
The statistics in this report indicate that the Program is continuing to be very successful in 
meeting this goal. The treatment of high-grade intraepithelial abnormalities has reduced the 
incidence of cervical cancer among women aged 20–69 from 17.1 per 100,000 women in 1991 
to 9.5 in 2001, and mortality has declined from 3.8 per 100,000 women in 1993 to 2.2 in 2003. 
The age-standardised participation rate among women in the target age range of 20–69 years 
for 2002–2003 was 60.7%; this is a small decline from 61.0% in 2000–2001. This is partly due to 
improvements in measurement by the screening programs of participation. However, the 
level of participation suggests that there is room for further improvement in the level of 
screening. This is of particular importance for Indigenous women whose cervical cancer 
incidence rate was higher than for other Australian women in the Northern Territory, 
Queensland, South Australia, Western Australia, the only jurisdictions for which adequate 
data were available (ABS & AIHW 2005).  
The main features in this report are as follows. 
Participation 
• From January 2002 to December 2003 there were 3,382,825 women screened in Australia 
for pre-cancerous changes to cervical cells; the target age group, 20–69 years, accounted 
for 98% of the women screened. 
• There was a decline in participation among younger women (20–44 years) and an 
improvement in participation for older women (45–69 years) in 2002–2003 when 
compared with 2000–2001; however, these changes were relatively small. Screening is 
particularly important for older women because they experience a relatively high 
incidence of cervical cancer. 
Early re-screening 
The recommended screening interval is 2 years following a negative smear.  
• Of a cohort of women screened in February 2002 (except for Queensland where the 21-
month period starts in March) who had a negative Pap smear result, 28% had a Pap 
smear or were screened again within 21 months. It is not known what proportion of this 
early re-screening is justified on clinical grounds. 
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• There has been a decline in the proportion of women following a normal Pap smear who 
are being re-screened within 21 months. For the 2002 cohort the early re-screening rate 
was 28%, whereas for the 2001 cohort it was 29.3%.  
Detection of abnormalities 
A low-grade abnormality includes atypia, warty atypia, possible cervical intraepithelial 
neoplasia (CIN), equivocal CIN, and CIN 1. A high-grade abnormality is defined to include 
CIN 1/2, CIN 2 and CIN 3 and adenocarcinoma in situ.  
• The ratio of histologically confirmed low-grade abnormalities to high-grade 
abnormalities was 1.24 for Australia in 2003 compared with 1.26 in 2002; the ratio has 
fluctuated each year between 1.24 and 1.47 since 1997.  
• In 2003, the National Cervical Screening Program detected 14,745 women in the target 
age group 20–69 years with high-grade abnormalities. In 2000, the first year when data 
for all jurisdictions were included, the rate was 7.5 per 1,000 women screened; the rate 
was also 7.5 in 2003. 
• The number of high-grade abnormalities detected per 1,000 women screened was highest 
in the younger age groups. For women under 30 years of age, the rate of high-grade 
abnormalities was over 16 per 1,000 women screened whereas it was less than 2 per 1,000 
for women aged 50–69 years. 
Incidence and mortality 
• The number of new cases of cervical cancer in Australia has continued to decline. There 
were 735 new cases in Australia in 2001 compared with 1,078 detected in 1990 before the 
start of the organised screening program. 
• In 2001 there were 98 new cases of micro invasive cancer for all women; all but 7 of these 
women were in the target age group, 20–69 years. The highest detection rates were for 
women in the 30–34 and 45–49 age groups. 
• Cervical cancer is the 18th most common cause of cancer mortality in women, accounting 
for 227 and 238 deaths in 2002 and 2003 respectively compared with 337 in 1990 before 
the start of the organised program. Although there was some fluctuation from year to 
year, the age-standardised mortality rate from cervical cancer declined between 1983 and 
2003. For all women there was a decline from 64.0 deaths per 100,000 women in 1983 to 
2.2 per 100,000 women in 2003. During the same period, for women in the target age 
group of 20–69 years, the rate declined from 5.4 per 100,000 to 2.2 per 100,000. 
• Women in the target age group from remote locations experienced relatively high 
incidence and mortality rates from cervical cancer compared with women in major cities. 
The differences were not statistically significant. However, between the periods  
1996–1999 and 2000–2003, the age-standardised cervical cancer mortality rate declined in 
all regions (major cities, regional and remote). 
• Before 1998, only Western Australia, South Australia and the Northern Territory had 
Indigenous mortality registration data of sufficient quality to be publishable. In 1998, 
Queensland’s coverage of Indigenous deaths reached an acceptable level to be included 
in the analysis of Indigenous mortality data. For these four jurisdictions, in the period 
2000–2003 there were 25 deaths from cervical cancer among Indigenous women in the 
target age group (an age-standardised mortality rate of 12.0 per 100,000 women). This is 
almost five times the corresponding rate in other Australian women (2.5 per 100,000 in 
2000–2003). 
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One year to 5 year comparison table for national data for all indicators 
 Latest reporting period  Previous reporting period  Five years ago 
Indicator Year  Rate  Year  Rate  Year  Rate 
Participation in 24- 
month period (%) 
 
2002–2003 
 
60.7% 
  
2000–2001 
 
61.0% 
  
1997–1998 
 
63.9% 
Early re-screening 
within 21 months of 
negative Pap smear 
 
February 
2002 cohort 
 
28% 
  
February 
2001 cohort 
 
29.2% 
  
 
Not available(a) 
Ratio of low- and 
high-grade 
abnormalities 
 
 
2003 
 
1.24 
  
 
2002 
 
1.26 
  
 
1998 
 
1.35 
High-grade 
abnormalities per 
1,000 women 
screened (age-
standardised rate) 
 
 
 
 
2003 
 
7.5 
  
 
 
 
2002 
 
7.5 
  
 
 
 
1998 
 
6.7(b) 
Incidence of cervical 
cancer per 100,000 
women (age-
standardised rate) 
 
 
 
2001 
 
9.5 
  
 
 
2000 
 
9.7 
  
 
 
1996 
 
13.4 
Mortality from 
cervical cancer per 
100,000 women 
(age-standardised 
rate) 
 
 
 
 
2003 
 
2.2 
  
 
 
 
2002 
 
2.1 
  
 
 
 
1998 
 
2.7 
(a) The indicator reported on a 24 month period following a negative Pap smear up to and including 1998; in 1999 the indicator was changed to 
a 21-month interval. 
(b) This age-standardised rate is not comparable to those for 2002 and 2003 because in 1998 data were not available for all jurisdictions. In 
addition, the 1998 age-standardised rate was standardised to the 1991 Australian population whereas the rates for 2002 and 2003 were 
standardised to the 2001 Australian population.  
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National cervical screening 
monitoring indicators 
This report monitors the performance of the National Cervical Screening Program using ten 
indicators which measure program activity, performance and outcome. These indicators help 
measure changes in disease patterns and examine the contribution of cervical screening to 
preventing or reducing deaths from cancer of the cervix.  
Screening indicators for the National Cervical Screening Program cover the areas of 
participation, early re-screening, low- and high-grade abnormality detection, incidence and 
mortality. These were developed and endorsed by the former National Advisory Committee 
and by state and territory cervical screening programs. A listing of the ten indicators and 
their definitions follows. The target age group for the National Cervical Screening Program is 
20–69 years. 
Indicator 1: Participation rate for cervical screening 
Percentage of women screened in a 24-month period by 5-year age groups (20–24, 25–29,  
30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69), for all ages (20–80+) and the target 
age group (20–69 years). 
Indicator 2: Early re-screening 
Proportion of women re-screened by number of re-screens during a 21-month period 
following a negative smear. 
Indicator 3: Low-grade abnormality detection  
Number of women with a histologically verified low-grade intraepithelial abnormality 
detected in a 12-month period as a ratio of the number of women with a histologically 
verified high-grade intraepithelial abnormality detected in the same period.  
Indicator 4: High-grade abnormality detection 
Detection rate for histologically verified high-grade intraepithelial abnormalities per 1,000 
women screened in a 12-month period by 5-year age groups (20–24, 25–29, 30–34, 35–39,  
40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age 
group (20–69 years, age-standardised).  
Indicator 5.1: Incidence of micro-invasive squamous cell carcinoma 
Incidence rate of micro-invasive squamous cell carcinoma per 100,000 estimated resident 
female population in a 12-month period by 5-year age groups (20–24, 25–29, 30–34, 35–39, 
40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age 
group (20–69 years, age-standardised). 
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Indicator 5.2: Incidence of squamous, adenocarcinoma, adenosquamous and 
other cervical cancer 
Incidence rate of squamous, adenocarcinoma, adenosquamous and other cervical cancers 
(micro-invasive and invasive) per 100,000 estimated resident female population in a  
12-month period by 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54, 
 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group (20–69 years,  
age-standardised).  
Indicator 6.1: Mortality 
Death rate from cervical cancer per 100,000 estimated resident female population in a  
12-month period by 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54,  
55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group (20–69 years,  
age-standardised). 
Periodic indicators 
Periodic indicators have been developed to report on issues of importance in monitoring the 
outcomes of the cervical screening program over a longer period of time than 1 year. This 
longer period allows for a greater aggregation of information on issues that are subject to 
wide annual fluctuations and for a more confident and meaningful estimate of the outcomes. 
The periodic indicators presented in this report are based on a reporting period of 4 years. 
Periodic incidence and mortality indicators by location 
Geographic region 
In reports before 2000–2001, analysis of incidence and mortality data by geographic region 
used the Rural, Remote and Metropolitan Areas (RRMA) classification. This classification 
was developed in 1994 by the then Department of Primary Industries and Energy and the 
then Department of Human Services and Health. It allows geographic regions to be classified 
into seven zones—two metropolitan, three rural and two remote zones.  
This report uses a more recent geographic classification instead of the RRMA classification. 
The new system, known as the Australian Standard Geographical Classification (ASGC), 
groups geographic areas into five classes. These classes are based on Census Collection 
Districts (CDs) and defined using the Accessibility/Remoteness Index for Australia (ARIA). 
ARIA is a measure of the remoteness of a location from the services provided by large towns 
or cities. A higher ARIA score denotes a more remote location. The five classes of the ASGC, 
along with a sixth ‘Migratory’ class, are listed in  
Table 1. 
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Table 1: The remoteness areas for the ASGC  
Region Collection districts within region 
Major cities of Australia CDs with an average ARIA index value of 0 to 0.2 
Inner regional Australia CDs with an average ARIA index value greater than 0.2 and less than or equal to 2.4 
Outer regional Australia CDs with an average ARIA index value greater than 2.4 and less than or equal to 5.92 
Remote Australia CDs with an average ARIA index value greater than 5.92 and less than or equal to 10.53 
Very remote Australia CDs with an average ARIA index value greater than 10.53  
Migratory Areas composed of off-shore, shipping and migratory CDs 
Source: ABS 2001. 
The ASGC is not directly comparable to the RRMA classification. Accessibility is judged 
purely on distance to one of the metropolitan centres. For example, the ASGC allocates 
Hobart to its second group (Inner regional Australia) and Darwin to its third group (Outer 
regional Australia), whereas the RRMA classification grouped them together with the other 
capital cities. 
Indicator 5.3: Incidence by location 
Incidence rate of cervical cancer per 100,000 estimated resident female population in a 4-year 
period by location and 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54,  
55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group (20–69 years, age-
standardised). 
Indicator 6.2: Mortality by location 
Death rate from cervical cancer per 100,000 estimated resident female population in a 4-year 
period by location  and 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54, 
55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group (20–69 years—age-
standardised). 
Indicator 6.3: Indigenous mortality 
Death rate from cervical cancer per 100,000 estimated resident female population in a 4-year 
period by Indigenous status and 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 
50–54, 55–59, 60–64, 65–69, 70–74, 75+) and for the target age group (20–69 years, age-
standardised). 
This indicator examines the patterns of mortality among Indigenous women.  
Identification of Indigenous status is still very fragmented and generally of poor quality in 
health data collections, and cervical screening data are no exception. Of the seven cervical 
screening indicators, only one indicator can be stratified by Indigenous status: mortality. 
Even for this, coverage is not complete. Only Western Australia, South Australia, the 
Northern Territory and Queensland are currently considered to have adequate coverage of 
Indigenous deaths in the registration of deaths. Therefore, only mortality data from these 
jurisdictions are analysed in this report. 
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Confidence intervals 
Where indicators include a comparison between states and territories, between time periods, 
between geographic locations or between Indigenous and other Australian women, a 95% 
confidence interval is presented along with the rates. This is because the observed value of a 
rate may vary owing to chance even where there is no variation in the underlying value of 
the rate. The 95% confidence interval represents a range over which variation in the observed 
rate is consistent with this chance variation. These confidence intervals can be used as an 
approximate test of whether changes in a particular rate are consistent with chance variation. 
Where the confidence intervals do not overlap, the change in a rate is greater than that which 
could be explained by chance.  
For example, the participation rate for Tasmania in 2002–2003 was 63.1% with a confidence 
interval of 62.6% to 63.5%. The corresponding rate for 2000–2001 was 65.2% with a 
confidence interval of 64.7% to 65.6%. These two intervals do not overlap, so the difference 
between the 2000–2001 and 2002–2003 rates is larger than we would expect due to chance 
alone.  
Another example is the comparison between cervical mortality rates for women in the target 
group in the remote areas. In the period 1996 to 1999 there were 5.2 cervical cancer deaths 
per 100,000 women in living remote areas. This rate had a confidence interval of 3.2 to 7.6. 
The 2000–2003 rate for women living in remote areas was 2.7 per 100,000, with a confidence 
interval of 1.5 to 4.4. These confidence intervals overlap, so despite the relatively large 
difference between the two observed rates they are still consistent with chance variation. This 
arises from the fact that remote areas of Australia have small populations, resulting in small 
numbers of deaths from any specific cause, and these rates may fluctuate from year to year 
over time. This in turn leads to relatively wide confidence intervals for an observed death 
rate. 
It is important to note that this result does not imply that the difference between the two 
rates is definitely due to chance. Instead, an overlapping confidence interval represents a 
difference in rates which is too small to differentiate between a real difference and one which 
is due to chance variation.  
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Participation 
The major objective of the National Cervical Screening Program is to reduce morbidity and 
deaths from cervical cancer by detecting treatable pre-cancerous lesions before their 
progression to cancer. Through increased participation, more women with pre-cancerous 
abnormalities can be detected and treated before progression to cervical cancer, thus 
reducing morbidity and deaths. In addition, increased participation will lead to the detection 
of more women with early stages of cancer where treatment can reduce mortality. 
The Program, through a variety of recruitment initiatives, focuses on women in the age 
group 20–69 years. The recommended screening interval for women in this target age group 
who have been sexually active at any stage in their lives is 2 years. Pap smears may cease at 
the age of 70 years for women who have had two normal Pap smears within the previous  
5 years. Women over 70 years who have never had a Pap smear, or who request a Pap smear, 
are screened. 
Some women in the target population are unlikely to require screening. They include: 
• those who have had a total hysterectomy with their cervix removed 
• those who have never been sexually active 
• women with a previously diagnosed gynaecological cancer. 
Participation rate calculations should, in principle, exclude all three groups from the data. In 
practice, the data are adjusted to remove women who have had a hysterectomy but the latter 
two groups cannot be excluded due to the lack of reliable data. 
State and territory programs have a range of strategies to increase participation of women in 
cervical screening. Such strategies include focusing on priority population groups including 
Indigenous women, rural and remote women, and women from culturally and linguistically 
diverse backgrounds. 
The objectives and usefulness of participation as an indicator are outlined below: 
• The participation indicator measures the proportion of the target population covered by 
the cervical screening program and the current screening policy of a 2-year interval.  
• The indicator is important in assessing the contribution of the cervical screening program 
to changes in incidence and mortality.  
• The indicator can be used as a means of evaluating the effect of communication and 
recruitment strategies, particularly if participation rates are analysed by demographic 
characteristics.  
• When this indicator is used in conjunction with others, it can be used to support analysis 
relating to target groups and screening intervals.  
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State- and territory-specific issues 
• Except for Victoria and the Australian Capital Territory, the participation rates are based 
on all women who were screened in the particular state or territory. This may lead to an 
over-estimation of numbers of women screened because of double counting of some 
women between states. This may be the result of difficulty in identifying state of 
residence for women in border areas, and inclusion of women resident overseas.  
Data issues 
• In 2001 the Australian Bureau of Statistics (ABS) carried out a full population census and 
a national health survey. These led to the revision of the ABS estimated resident 
population (ERP) data, the introduction of a new Australian standard population for use 
in age-standardisation and the production of new estimates of hysterectomy status 
among Australian women. The denominators for participation rates presented in this 
report have been calculated using the 2001 ABS National Health Survey hysterectomy 
fractions and the revised ERP values, and age-adjusted using the 2001 Australian 
standard population. The denominators for the equivalent rates in previous reports were 
calculated using the 1995 ABS National Health Survey hysterectomy fractions and 
unrevised ERP values, and age-adjusted using the 1991 Australian standard population. 
The combined effect of these changes is that participation rates presented in this report 
are on average between 1 and 2 percentage points lower than equivalent rates in previous 
reports. 
• Recent fluctuations in participation rates are, in some jurisdictions, partly due to more 
accurate tracking of individual screening participants over time; this has led to an 
apparent decrease in recorded participation rates by up to 3 percentage points. There has 
also been variation over time and between jurisdictions in the use of short-term mass 
media campaigns which, in addition to any long-term effect, may have led to short-term 
fluctuations in screening participation.  
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Indicator 1: Participation rate for cervical screening 
Percentage of women screened in a 24-month period by 5-year age groups (20–24, 25–29, 
30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+), for all ages 
(20–80+) and for the target age group (20–69 years). 
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 Refer to Tables 1b and 2b (pages 36 and 38). 
 Notes  
 1. Participation rates have been adjusted for the estimated proportion of women who have had a hysterectomy. 
 2. These data exclude women who have opted not to be on the register. 
 Source: AIHW analysis of state and territory Cervical Cytology Registry data. 
 Figure 1: Participation in the National Cervical Screening Program  
by age group, Australia, 2000–2001 and 2002–2003 
 
 
*Age-standardised rates (standardised to the Australian 2001 population) with 95% confidence intervals. 
• From January 2002 to December 2003 there were 3,382,825 women screened in Australia 
for pre-cancerous changes to cervical cells. Of these women, 3,318,354 (98%) were in the 
target age group 20–69 years (Table 2a, page 37). 
• The age-standardised participation rate for women aged 20–69 years was 61.0% in  
2000–2001 and 60.7% in 2002–2003 (Tables 1b and 2b, pages 36 and 38). 
 Age group 
24-month 
period 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 20–69*
 (Per cent) 
2000–2001 50.3 61.0 64.9 64.8 64.4 65.0 63.0 64.9 55.3 46.7 61.0 (60.9–61.1)
2002–2003 49.0 59.0 63.4 63.9 64.1 65.6 63.1 66.2 56.4 48.8 60.7 (60.6–60.8)
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• There was a decline in participation among younger women (20–44 years) and an 
improvement in participation for older women (45–69 years) in 2002–2003 when 
compared with 2000–2001; however, these changes were relatively small. 
• Participation in 2002–2003 was lower among women aged in their twenties and sixties 
than in the other age groups in the target population. 
• Participation has risen among women aged 45 years and older; however, the level is still 
relatively low for women in their sixties. It is important for the Program to achieve 
further increases in screening levels for women in their sixties because they experience 
some of the highest incidence of cervical cancer in the target population with 11.5 and 
12.4 per 100,000 women aged 60–64 and 65–69 respectively (Tables 2b and 24, pages 38 
and 65).  
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 Notes 
 1. Rates are expressed as the percentage of the eligible female population and age-standardised to the 
 Australian 2001 population. 
 2. Bars on graphs represent 95% confidence intervals. 
 Source: AIHW analysis of state and territory Cervical Cytology Registry data. 
 Figure 2: Participation (age-standardised) in the National Cervical Screening Program  
by women aged 20–69 years, states and territories, 2000–2001 and 2002–2003 
 
 
24-month 
period/ rate NSW Vic(a) Qld WA SA Tas ACT(a) NT Australia
2000–2001     
AS rate 59.1 64.6 57.0 61.4 64.9 65.2 62.8 61.7 61.0
95% CI 59.0–59.3 64.5–64.8 56.8–57.1 61.2–61.6 64.6–65.1 64.7–65.6 62.3–63.4 61.0–62.4 60.9–61.1
2002–2003     
AS rate 58.8 64.2 57.2 60.6 65.1 63.1 62.7 60.2 60.7
95% CI 58.7–58.9 64.1–64.4 57.0–57.3 60.3–60.8 64.8–65.3 62.6–63.5 62.2–63.3 59.5–60.9 60.6–60.8
(a) The Victorian and Australian Capital Territory registries only register women with a Victorian or Australian Capital Territory address 
respectively. 
• There were small but statistically significant decreases in participation between 
2000–2001 and 2002–2003 in New South Wales, Victoria, Western Australia, Tasmania 
and Northern Territory. 
• Participation rates varied across the states and territories among women aged  
20–69 years in 2002–2003, ranging from 65.1% in South Australia to a low of 57.2% in 
Queensland. 
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Early re-screening 
The National Cervical Screening Program seeks to maximise reductions in incidence and 
mortality of cervical cancer within a cost-effective framework. The screening program 
defines two key parameters for achieving these objectives—target populations and screening 
intervals. Compliance with these parameters is crucial to maintaining the effectiveness of the 
program and cost efficiency so that resources may be used to increase population coverage. 
For most women who have a negative smear, the recommended interval before their next 
screen is 2 years.  
An early re-screen is defined as having a repeat Pap smear within 21 months of a negative 
smear result. Reasons for the choice of 21 months as the time line for reporting are discussed 
under ‘Data issues’ below. 
This indicator: 
• tracks over a period of 21 months a cohort of women from all states and territories who 
had a negative smear result in February 2002 to determine the extent of early re-screening 
within the National Cervical Screening Program. The exception to this is Queensland 
where the index month is March. February was selected as the index month nationally 
because it has been shown to be a relatively stable month in terms of the number of 
women who are screened. This pattern has been consistent over a number of years, partly 
because fewer women take holidays at this time. It is also helped by the fact that 
February is not a month during which public holidays are nationally gazetted. 
• measures the compliance with the recommended screening interval following a negative 
smear. 
• is important in assessing screening coverage around the recommended interval, as 
significant differences may reduce program effectiveness. 
This indicator should be interpreted with caution as some early re-screening after a negative 
Pap smear report is appropriate and in accordance with the National Health and Medical 
Research Council guidelines. Specifically, if a woman has a history of histologically proven 
high-grade abnormality, then annual screening is recommended. If a woman is being 
monitored after treatment or during the resolution phase of a low-grade abnormality, it is 
appropriate for her to be screened earlier than the 24 months recommended screening 
interval.  
Data issues 
The data for Indicator 2 published in reports before the Cervical Screening in Australia 1999–
2000 report are not directly comparable with the data in this report as this indicator has been 
modified to change the follow-up period from 24 months to 21 months. This change was 
made because women often have their Pap smear taken at a time convenient to them, with 
some choosing to have their biennial screening immediately before the 24-month 
anniversary. Also prescriptions for oral contraceptives lapse at 22 months and some women 
are then likely to combine their Pap smears with their visit to the GP for renewing their 
scripts.  
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Indicator 2: Early re-screening 
Proportion of women re-screened by number of re-screens during a 21-month period 
following a negative Pap smear. 
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 Refer to Table 4 (page 39). 
 Notes  
 1. The reference period for this indicator was the 21 months following the index months February 2001  
 and February 2002 (or March 2001 and March 2002 for Queensland). 
2. The data for the 2001 cohort is not comparable with the data published in Cervical Screening in  
 Australia 2001–2002 because Northern Territory data have been included in this report. 
 Source: AIHW analysis of state and territory Cervical Cytology Registry data. 
 Figure 3: Proportion of women re-screened by number of screens during the 21-month 
period following a negative Pap smear in the 2001 and 2002 cohorts, Australia 
 
 
Cohort 0 screens 1 screen 2 screens 3+ screens 
 (Per cent) 
2001 70.8 25.3 3.1 0.8 
2002 72.0 24.1 3.1 0.8 
• A cohort of 167,421 women screened in February 2002 (except for Queensland where the 
21-month period starts in March) whose Pap smear results were normal was tracked over 
a 21-month period to measure the extent of early re-screening in Australia. A smaller 
proportion of women in the 2002 cohort were re-screened early than in the previous 
cohort. 
• Of the 2002 cohort, 24.1% were re-screened within 21 months, and a further 3.9% were re-
screened two or more times. 
• The proportion of women who did not have any additional Pap smears within 21 months 
following a negative result increased from 70.8% in 2000–2001 to 72.0% in 2002–2003.  
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 Refer to Table 4 (page 39). 
 Note: The reference period for this indicator was the 21 months following the index month February 2002.  
 Source: AIHW analysis of state and territory Cervical Cytology Registry data. 
 Figure 4: Proportion of women re-screened by number of screens during the 21-month 
period following a negative Pap smear in the 2002 cohort, states and territories 
 
 
No. of 
screens NSW Vic Qld WA SA Tas ACT NT Australia 
 (Per cent) 
0 screens 72.0 69.5 73.3 71.9 77.3 74.9 74.1 75.1 72.0 
1 screen 24.6 25.8 22.5 24.6 20.1 21.9 22.2 20.5 24.1 
2 or more 3.4 4.7 4.2 3.5 2.6 3.2 3.7 4.4 3.9 
• South Australia (77.3%), Northern Territory (75.1) and Tasmania (74.9%) had the highest 
proportions of women who were not re-screened in the 21 months following their 
negative Pap smears in 2002. 
• Victoria (30.5%), Western Australia (28.1%) and New South Wales (28.0%) had the 
highest proportions of re-screens and the lowest proportion of re-screens within  
21 months occurred in South Australia (22.7%).  
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Low-grade abnormalities 
The Pap smear test is able to identify a range of abnormalities in cervical cells. Some of these 
abnormalities have a greater chance of becoming malignant (high-grade abnormalities), and 
are therefore treated aggressively. The chance of low-grade abnormalities progressing to 
malignant change is lower. 
In this report a low-grade intraepithelial abnormality includes:  
• atypia;  
• warty atypia (human papilloma virus (HPV) effect);  
• possible cervical intraepithelial neoplasia (CIN) (see glossary);  
• equivocal CIN;  
• CIN 1; and  
• endocervical dysplasia not otherwise specified (NOS). 
The indicator is the ratio of low-grade to high-grade intraepithelial abnormalities, all 
histologically verified.  
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Indicator 3: Low-grade abnormality detection 
Ratio of number of women with a histologically verified low-grade intraepithelial 
abnormality detected in a 12-month period to the number of women with a histologically 
verified high-grade intraepithelial abnormality detected in the same period. 
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 Refer to Tables 5a and 5b (page 40). 
 Source: AIHW analysis of state and territory Cervical Cytology Registry data. 
 Figure 5: Ratio of low-grade to high-grade abnormalities in women aged  
20–69 years, states and territories, 2002 and 2003 
 
 
Year NSW Vic Qld WA SA Tas ACT NT Australia 
 (Ratio) 
2002 1.29 0.91 1.40 1.62 1.27 1.13 1.31 1.42 1.26 
2003 1.41 0.95 1.11 1.71 1.32 0.96 1.06 1.31 1.24 
• The ratio of histologically confirmed low-grade abnormalities to high-grade 
abnormalities found in women aged 20–69 years in Australia declined from 1.26 in  
2002 to 1.24 in 2003.  
• In 2003 there was some variation between states and territories, with the highest ratio in 
Western Australia (1.71); Victoria (0.95) had the lowest ratio. 
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High-grade abnormalities 
High-grade lesions have a greater probability of progressing to invasive cancer than do low-
grade lesions. Therefore, one of the aims of the National Cervical Screening Program is to set 
a screening interval that detects most of these lesions before they progress and become 
invasive. This indicator measures the frequency of this type of abnormality in the screened 
community. A high-grade intraepithelial abnormality is defined in this report as CIN 1/2, 
CIN 2, CIN 3 or adenocarcinoma in situ.  
The National Health and Medical Research Council has produced guidelines to assist in the 
management of women who have low- and high-grade intraepithelial abnormalities (DHSH 
1994b). These are summarised in Appendix F. 
State- and territory-specific issues 
• The reference period for Indicator 4 was the 12 months from January to December 2003 
for all states and territories. 
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Indicator 4: High-grade abnormality detection 
Detection rate for histologically verified high-grade intraepithelial abnormalities per 1,000 
women screened in a 12-month period by 5-year age groups (20–24, 25–29, 30–34, 35–39,  
40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age 
group (20–69 years, age-standardised). 
 
20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69
0
2
4
6
8
10
12
14
16
18
20
HGAs detected per 1,000 women screened
Age group
2002
2003
 
 Refer to Tables 6a and 6b (pages 41 and 42). 
 Note: The reference period for this indicator is from January to December 2003. 
 Source: AIHW analysis of State and Territory Cervical Cytology Registry data. 
 Figure 6: High-grade abnormalities per 1,000 women by age group,  
Australia, 2002 and 2003 
 
 
 Age group 
Year 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 20–69* 
 (Number per 1,000 women) 
2002 18.9 16.7 11.3 6.9 4.8 3.0 2.0 1.7 1.3 1.4 7.5 (7.4–7.6) 
2003 18.5 16.9 11.0 6.9 5.0 3.2 1.8 1.5 1.6 1.4 7.5 (7.4–7.6) 
*Age-standardised rates (standardised to the Australian 2001 population) with 95% confidence intervals. 
• In 2003, there were 14,745 histologically verified high-grade abnormalities detected in 
1,880,240 women screened in the target age range 20–69 years (0.8%). The same detection 
rate also applied in 2002 (Table 7b, page 44). 
• The age-standardised detection rate for histologically verified high-grade intraepithelial 
abnormalities was 7.5 per 1,000 women in the target age group, 20–69 years, in 2002 and 
in 2003. 
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• The age-specific detection rate of high-grade intraepithelial abnormalities for women 
aged 20–69 years increased slightly between 2002 and 2003 in the 25–29, 40–49 and 60–64 
age groups and declined in all the other age groups except in the 35–39 and 65–69 age 
groups where there was no change.  
• In 2003, the National Cervical Screening Program detected 14,725 women in the target 
age group 20–69 years with high-grade abnormalities. In 2000, the first year when data 
for all jurisdictions were included, the age-standardised rate was 6.9 (standardised to the 
2001 Australian population) per 1,000 women screened; this increased to 7.5 in 2003. 
• The rate of high-grade abnormalities detected was much higher in the younger age 
groups. In the 20–24 age group the rate was 18.5 per 1,000 women screened compared 
with less than 2 per 1,000 women aged 50–54 years and older. This age-specific 
distribution is the inverse of the pattern for cervical cancer mortality.  
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 Refer to Tables 9a and 9b (pages 47 and 47). 
 Notes 
 1. The reference period for this indicator is from January to December 2003. 
 2. Rates are standardised to the 2001 Australian total population. 
 3. Bars on graphs represent 95% confidence intervals. 
 Source: AIHW analysis of state and territory Cervical Cytology Registry data. 
 Figure 7: Age-standardised rate of high-grade abnormalities per 1,000 women  
screened aged 20–69 years, states and territories, 2002 and 2003 
 
 
AS rate NSW Vic Qld WA SA Tas ACT NT Australia 
2002 7.9 6.3 8.7 7.9 6.2 8.9 7.1 10.6 7.5 
95% CI 7.7–8.1 6.1–6.5 8.4–9.0 7.5–8.3 5.8–6.6 8.1–9.8 6.3–8.1 9.1–12.1 7.4–7.6 
2003 7.2 7.1 8.5 7.8 6.4 7.5 9.3 10.7 7.5 
95% CI 7.0–7.4 6.8–7.3 8.2–8.8 7.4–8.2 6.0–6.8 6.7–8.3 8.3–10.5 9.3–12.3 7.4–7.6 
• In 2003, Northern Territory had the highest rate of 10.7 high-grade abnormalities 
detected per 1,000 women screened and South Australia had the lowest with 6.3 for 
women in the target age group, 20–69 years. 
• Detection of high-grade abnormalities increased between 2002 and 2003 in Victoria, 
South Australia, Australian Capital Territory and Northern Territory, but only the 
increases in Victoria and Australian Capital Territory were statistically significant. 
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Incidence 
A major objective of the National Cervical Screening Program is to minimise the incidence of 
cervical cancer by detecting treatable pre-cancerous lesions before their progression to 
cancer. However, where these pre-cancerous lesions cannot be detected, diagnosis of cancer 
at its earliest stage, the micro-invasive stage, is the most desirable outcome. The next two 
indicators measure the incidence rates of micro-invasive and all cervical cancers in the 
community.  
In 1994 the International Federation of Gynaecology and Obstetrics endorsed the following 
definition of micro-invasive carcinoma of the cervix: 
Stage 1a1.  Measured invasion of stroma no greater than 3 mm in depth and no wider than  
7 mm. 
Stage 1a2.  Measured invasion of stroma between 3 mm and 5 mm in depth and no wider 
than 7 mm. The depth of invasion should be measured from the base of the 
epithelium, either surface or glandular, from which it originates. Vascular space 
involvement, either venous or lymphatic, should not alter the staging (Ostor & 
Mulvany 1996). 
In interpreting cervical cancer incidence statistics, note that cervical screening has been 
available on an ad hoc basis since the 1960s, but it is only since the late 1980s and early 1990s 
that there has been an organised national approach to screening at a population level. The 
introduction of cervical screening programs which achieve higher participation rates may 
result in the paradox whereby in the short term the number of new cases of micro-invasive 
cancer increases because cancers are found earlier than they would have been without 
screening, but the rate of more advanced cancers decreases in the longer term.  
For this report the most recent national data available on incidence are for 2001, in contrast to 
screening data and mortality data which are available for 2003. This time lag in availability of 
incidence data is expected to reduce over the next 2 years. 
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Indicator 5.1: Incidence of micro-invasive cervical 
cancer 
Incidence rates of micro-invasive squamous cell carcinoma per 100,000 estimated resident 
female population in a 12-month period by 5-year age groups (20–24, 25–29, 30–34, 35–39, 
40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age 
group (20–69 years, age-standardised). 
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 Refer to table 11 (page 49) 
 Note: Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population 
 Source: National Cancer Statistics Clearing House (AIHW). 
 Figure 8: Age-standardised incidence rates for micro-invasive squamous cell  
cancer, women aged 20–69 years, Australia, 1990–2001 
 
 
 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001
 (Number per 100,000 women) 
AS rate 
(20–69 years) 2.8 2.9 2.8 2.6 3.0 3.2 2.5 2.0 2.1 1.5 1.5 1.5
 
• The age-standardised incidence rate of micro-invasive cervical cancer was 1.5 per 100,000 
women in 2001 for women in the target age group of 20–69 years and 1.0 per 100,000 for 
women of all ages (0–85+ years) (Table 11, page 49). The 20–69 age group rates fell 
sharply between 1995 and 1999 and then stabilised between 1999 and 2001 at 1.5 per 
100,000 women.  
• In 2001 there were 98 new cases of micro-invasive cervical cancers for women of all ages 
(0–85+ years) and 91 new cases in women aged 20–69 years (Table 10, page 48). 
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 Note: Rates are expressed per 100,000 women. 
 Source: National Cancer Statistics Clearing House (AIHW). 
 Figure 9: Age-specific incidence rates of micro-invasive squamous cell cancer, women 
aged 20–69 years, Australia, 2000 and 2001 
 
 
 Age group 
Year 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 20–69* 
2000 0.2 1.7 3.5 1.9 1.1 2.4 1.0 0.8 0.8 0.0 1.5 (1.2–1.8) 
2001 0.3 1.7 3.0 2.0 0.8 2.2 1.4 0.8 1.0 0.6 1.5 (1.2–1.8) 
*Age-standardised rates (standardised to the Australian 2001 population) with 95% confidence intervals. 
 
• In both 2000 and 2001, the highest detection rates for micro-invasive squamous cell 
cancer were for women in the 30–34 age group. The rate declined with age in both years 
to rates of 1.4 per 100,000 and below for women aged 50 years or more; however, there 
was some fluctuation in the age-specific incidence rates for women aged 35–45 years, 
• In 2001 there were 22 cases of micro-invasive squamous cell cancer in women aged  
30–34 years. The number of cancers declined to less than 10 for women aged 50–69 years. 
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Indicator 5.2: Incidence of squamous, 
adenocarcinoma, adenosquamous and other 
cervical cancer 
Incidence rates of squamous, adenocarcinoma, adenosquamous and other cervical cancer 
(micro-invasive and invasive) per 100,000 estimated resident female population in a  
12-month period by 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54,  
55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group (20–69 years,  
age-standardised). 
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 Refer to Table 13 (page 54). 
 
Note: Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population. 
 Source: National Cancer Statistics Clearing House (AIHW). 
 Figure 10: Age-standardised incidence rates of cervical cancer, Australia, 1990–2001 
 
 
Age 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001
 (Number per 100,000 women) 
All ages 
0–85+ years 13.4 13.2 12.2 11.9 13.0 10.7 10.3 8.7 9.0 8.3 7.7 7.3
Target age 
20–69 years 17.7 17.1 16.0 15.8 16.9 13.8 13.4 11.3 11.6 10.9 9.7 9.5
 
• In 2001, there were 735 new cases of cervical cancer diagnosed in Australia compared 
with the peak of 1,136 new cases in 1994. Of the 735 new cases, 584 were women in the 
target age group 20–69 years (Table 12, page 50). All but two cases of the remaining 151 
were in women aged 70 years and over. 
• The age-standardised incidence rate of all cervical cancers declined to 7.3 per 100,000 
women for women of all ages (0–85+ years) in Australia in 2001, and to 9.5 per 100,000 
women in the target group. Between 1990 and 2001 the decline over all ages was 45.1%, 
and in the target age group was 46.7% (Table 13, page 51). 
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 Refer to Table 13 (page 51). 
 Note: Rates are expressed per 100,000 women. 
 Source: National Cancer Statistics Clearing House (AIHW). 
 Figure 11: Age-specific incidence rates of cervical cancer, Australia, 2000 and 2001 
 
 
 Age group 
Year 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 20–69
 (Number per 100,000 women) 
2000 1.1 5.5 11.7 9.3 11.1 11.1 9.5 11.8 15.6 15.1 9.7
2001 1.1 5.8 8.0 11.7 9.0 14.8 12.0 10.7 11.5 12.4 9.5
 
• The age-specific rate of cervical cancer incidence was highest in 2001 for women aged  
45–49 with 14.8 per 100,000 women. Although age-specific rates for women in their 
sixties and seventies have declined since 2000, they remain high.  
• The 2001 age-specific rate of cervical cancer incidence increased for women in the 35–39, 
45–49 and 50–54 age groups. 
• Figure 11 shows two distinct peaks in age-specific cervical cancer in 2001, the 30–34 and 
45–49 age groups; however, the underlying trend is rising incidence with increasing age. 
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 Refer to Tables 14b and 15b (pages 53 and 55). 
 Notes 
 1. Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population. 
 2. Bars on graphs represent 95% confidence intervals. 
 Source: National Cancer Statistics Clearing House (AIHW). 
 Figure 12: Age-standardised cervical cancer incidence rates in women aged  
20–69 years, states and territories, 1994–1997 and 1998–2001 
 
 
 NSW Vic Qld WA SA Tas ACT NT Australia
1994–1997 13.8 13.8 15.3 13.9 9.9 14.5 12.4 26.2 13.8
95% CI 13.0–14.6 12.9–14.8 14.1–16.6 12.4–15.6 8.6–11.5 11.6–17.9 9.0–16.6 18.1–36.3 13.3–14.3
1998–2001 10.7 8.6 12.3 11.0 9.2 12.3 7.8 16.3 10.4
95% CI 10.0–11.5 7.9–9.3 11.3–13.4 9.7–12.4 7.9–10.7 9.7–15.5 5.3–11.0 10.7–23.5 10.0–10.8
 
• In the period 1998–2001, the Australian Capital Territory had the lowest incidence at 7.8 
new cases per 100,000 women and the Northern Territory had the highest rate of 16.3 per 
100,000 women.  
• The age-standardised incidence rate declined in all states and territories between the two 
periods 1994–1997 and 1998–2001. The declines were significant in New South Wales, 
Victoria and Queensland; the national average was also significantly lower than in the 
earlier period. 
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 Refer to Table 16b (page 56). 
 Note: Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population. 
 Source: National Cancer Statistics Clearing House (AIHW). 
 Figure 13: Age-standardised incidence rates of cervical cancer by histological type, 
women aged 20–69 years, Australia, 1990–2001 
 
 
Histological type 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001
Squamous 12.4 12.2 11.3 11.1 11.3 9.6 9.3 7.8 8.1 7.7 6.5 6.4
Adenocarcinoma 2.9 2.8 2.7 2.6 3.5 2.6 2.6 2.2 2.4 2.2 2.0 1.9
Adenosquamous 1.0 0.8 1.0 0.9 0.7 0.6 0.7 0.6 0.5 0.4 0.5 0.5
Other 1.5 1.4 1.0 1.2 1.4 0.9 0.8 0.8 0.6 0.7 0.8 0.7
 
• In 2001, squamous cell carcinomas of the cervix accounted for 67.3% of all new cases of 
cervical cancer in women aged 20–69 years, adenocarcinomas 19.9%, adenosquamous 
5.1%, and the remaining 7.9% a range of other mixed and unknown histologies (Table 
16a, page 56). 
• The trend from 1990 to 2001 for all histological types has been a decrease in the age-
standardised rates of cervical cancer per 100,000 women aged 20–69 years; the difference 
in the rates between 1990 and 2001 is statistically significant for all types except 
adenosquamous. 
• The incidence rates for all histological types of cervical cancer have almost halved since 
1990, before the start of the national screening program. 
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Indicator 5.3: Incidence by location 
Incidence rates of cervical cancer per 100,000 estimated resident female population in a  
3-year period by location by 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49,  
50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group  
(20–69 years, age-standardised). 
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 Refer to Table 19 (page 59). 
 Notes 
 1. The age-standardised rates are presented as 4-year rolling blocks of data.  
 2. Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population. 
 3. Bars on graphs represent 95% confidence intervals. 
 4. The ASGC has been used in this report; previous reports used the RRMA classification (see page 2). 
 Source: National Cancer Statistics Clearing House (AIHW). 
 Figure 14: Age-standardised incidence rates of cervical cancer in women aged  
20–69 years, by location, Australia, 1994–1997 and 1998–2001 
 
 
 Metropolitan  Regional  Remote 
 1994–1997 1998–2001 1994–1997 1998–2001 1994–1997 1998–2001 
AS rate 13.7 10.0 13.2 10.6 18.0 14.3 
95% CI 13.1–14.3 9.5–10.5 12.4–14.1 9.9–11.4 14.4–22.1 11.3–17.9 
 
• There were 2,046 new cases (66.1% of all new cases) of cervical cancer in major cities in 
the 4-year period 1998–2001, 965 new cases (31.2% of all new cases) in regional locations 
and 85 new cases (2.7% of all new cases) in remote locations (Table 18, page 58).  
• Age-standardised cervical cancer incidence rates in the period 1998–2001, for women in 
the target age group 20–69 years, were higher in remote locations (14.3 per 100,000 
women) than in regional locations (10.6) and major cities (10.0). The difference in cervical 
cancer rates for women in the target age groups in remote locations was significantly 
higher than for women in major cities (Table 19, page 59). 
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Mortality 
Cancer of the cervix is one of the few cancers for which there is an efficacious screening test 
for detection of precursors of the disease. Most deaths due to cervical cancer are potentially 
avoidable (Marcus & Crane 1998). The objective of the National Cervical Screening Program 
is to reduce this mortality rate. 
The three mortality indicators are mortality (by age and state), mortality by location 
(metropolitan, rural and remote), and Indigenous mortality (Indigenous and other 
Australian women). These indicators measure the level of mortality from cervical cancer in 
the total female population by age and other demographic characteristics. The mortality 
indicators are important because from them an assessment can be made of changes in 
mortality in different age groups and particular target groups over time. However, note that 
changes in the mortality rates may not be evident for a number of years following an 
improvement in the participation rate. Therefore, the effectiveness of this measure needs to 
be viewed in the longer rather than the shorter term.  
Data issues 
• Two major changes that have occurred in the classification and processing of Australian 
mortality data require some caution when interpreting mortality data over time. They 
are: 
1. the introduction of the tenth revision of the International Classification of Diseases 
(ICD–10) for classifying deaths registered from 1 January 1999; and 
2. the introduction by the Australian Bureau of Statistics (ABS) of the Automated 
Coding System (ACS) for processing deaths registered from 1 January 1997. 
• As a result, there is now a break in the mortality data series. In order to make mortality 
data coded using ICD–9 and ICD–10 comparable, the ABS has derived comparability 
factors to adjust data based on ICD–9. These comparability factors are derived from the 
movements in the underlying causes of death coded in ICD–9 compared with ICD–10 
(ABS 2000). 
• For cervical cancer deaths, the comparability factor is 0.98, and the pre-1997 mortality 
data presented in this report have been adjusted accordingly. The effect of this is that the 
pre-1997 number of deaths appearing in this report are different from figures in most 
earlier Cervical Screening in Australia reports. 
• Before 1998, only South Australia, Western Australia and the Northern Territory had a 
relatively high coverage of Indigenous status identification in the deaths data. In 1998 
Queensland’s coverage of Indigenous deaths reached an acceptable level following the 
introduction of a new Death Information Form in 1996–1997 which included a question on 
Indigenous status (ABS 1999). Therefore, in this report, cervical cancer deaths for 
Indigenous Australians include data from Queensland (for 1998 to 2000), South Australia, 
Western Australia and the Northern Territory. 
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Indicator 6.1: Mortality 
Death rate from cervical cancer per 100,000 estimated resident female population in a  
12-month period by 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54,  
55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group (20–69 years,  
age-standardised). 
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  Refer to Table 21 (page 61).  
  Notes 
  1. Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population. 
  2. Deaths were derived by year of registration. 
  Source: AIHW Mortality Database. 
   Figure 15: Age-standardised death rates from cervical cancer, Australia, 1983–2003 
 
 
• Cervical cancer was the 18th most common cause of cancer deaths in Australian women 
in 2003, accounting for 238 deaths.  
• The age-standardised death rate for women of all ages (0–85+ years) was 2.2 per 100,000 
women in 2003, much lower than the peak of 5.0 per 100,000 women in 1985, which was 
before the introduction of the organised screening program (this represents a 56% 
decrease in mortality over this period).
 ’83 ’84 ’85 ’86 ’87 ’88 ’89 ’90 ’91 ’92 ’93 ’94 ’95 ’96 ’97 ’98 ’99 ’00 ’01 ’02 ’03
All ages 
0–85+ years 4.9 4.7 5.0 4.7 4.4 4.5 4.5 4.2 4.0 3.8 3.6 3.8 3.7 3.2 3.1 2.7 2.2 2.6 2.5 2.1 2.2
Target age  
20–69 years 5.4 4.9 5.0 5.2 4.4 4.6 4.6 4.8 4.0 3.5 3.8 4.1 3.8 3.0 3.0 2.7 2.1 2.6 2.5 2.1 2.2
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 Notes 
 1. Rates are expressed per 100,000 women. 
 2. Deaths were derived by year of registration. 
 Source: AIHW Mortality Database. 
 Figure 16: Age-specific cervical cancer death rates by age group, Australia, 1990–1993  
and 2000–2003 
 
 
 Age group 
Period 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
1990–1993 0.1 0.8 1.8 3.6 4.5 5.5 4.7 6.3 8.5 9.5 12.7 13.6 14.8 22.7
2000–2003 0.1 0.4 1.3 1.5 1.9 3.2 3.5 3.5 5.4 5.9 8.0 9.4 11.9 13.4
 
• Mortality from cervical cancer between the 1990–1993 and 2000–2003 periods declined in 
all age groups except for the age group 20–24 years, where there was no difference. The 
decline in mortality rates, particularly for the oldest age groups in 2000-2003, is evident  
in Figure 16 when compared with the earlier period. 
• In both 1990–1993 and 2000–2003 the age-specific rates of cervical cancer mortality 
climbed with increasing age.  
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 Refer to Tables 23 and 25 (pages 63 and 65). 
 Notes 
 1. The age-standardised rates were averaged over 4 years to smooth annual variations that may occur in the  
 smaller states and territories.  
 2. Deaths derived by year and state of registration. 
 3. Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population.  
 4. Bars on graphs represent 95% confidence intervals. 
 Source: AIHW Mortality Database. 
 Figure 17: Age-standardised cervical cancer death rates in women aged  
20–69 years, states and territories, 1996–1999 and 2000–2003 
 
 
 NSW Vic Qld WA SA Tas ACT NT Australia
Rate 1996–1999 2.8 2.1 2.9 3.1 1.8 4.4 4.4 6.7 2.7
95% CI 2.5–3.2 1.8–2.5 2.4–3.4 2.4–3.9 1.3–2.5 2.9–6.4 2.5–7.2 3.0–12.4 2.5–2.9
Rate 2000–2003 2.3 1.7 2.5 2.7 2.7 3.4 2.5 4.6 2.3
95% CI 2.0–2.7 1.4–2.1 2.1–3.0 2.1–3.5 2.1–3.6 2.1–5.2 1.2–4.6 1.9–9.0 2.1–2.5
 
• In the 4-year period 2000–2003 there were 994 deaths from cervical cancer in all states 
and territories compared with 1,081 in 1996–1999. 
• Age-standardised mortality varied from 1.7 deaths per 100,000 women in Victoria to 4.6 
per 100,000 women in the Northern Territory in the 2000–2003 period. 
• The age-standardised death rates decreased in all jurisdictions between the two periods 
except in South Australia. Although the Northern Territory rate decreased sharply 
between the two periods, the rates are based on very small numbers and are subject to 
considerable variation. 
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Indicator 6.2: Mortality by location 
Death rate from cervical cancer per 100,000 estimated resident female population in a  
4-year period by location and 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 
50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group  
(20–69 years, age-standardised). 
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 Refer to Table 27 (page 67). 
 Notes 
 1. Age-standardised rates are presented as 4-year rolling blocks of data.  
 2. Deaths were derived from place of usual residence and by year of registration.  
 3. Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population.  
 4. Bars on graphs represent 95% confidence intervals. 
 5. The ASGC has been used in this report and the 2001–2002 report; previous reports used the RRMA  
 classification (see page 2). 
 Source: AIHW Mortality Database. 
 Figure 18: Age-standardised cervical cancer death rates by location, women aged  
20–69 years, 1996–1999 and 2000–2003 
 
 
 Major cities  Regional  Remote 
 1996–1999 2000–2003 1996–1999 2000–2003 1996–1999 2000–2003
Rate 2.5 2.2 2.8 2.6 5.2 2.7
95% CI 2.3–2.8 1.9–2.4 2.5–3.2 2.2–3.0 3.2–7.6 1.5–4.4
• During the 4-year period 2000–2003, there were 622 deaths (63% of all cervical cancer 
deaths in that period) in major cities, 340 deaths (34% of all cervical cancer deaths) in 
regional areas and 26 deaths (3% of all cervical cancer deaths) in remote areas (Table 26, 
page 66).  
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• In all three regions the age-standardised mortality rates declined between the periods 
1996–1999 and 2000–2003; however, the declines were not statistically significant. The 
largest overall mortality reduction, of 33%, was in remote areas, but these rates are based 
on small numbers and should be treated with caution.  
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Indicator 6.3: Indigenous mortality 
Death rate from cervical cancer per 100,000 estimated resident female population in a  
4-year period by Indigenous status and 5-year age groups (20–24, 25–29, 30–34, 35–39,  
40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75+) and for the target age group  
(20–69 years, age-standardised). 
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 Rrefer to Table 28 (page 68). 
 Notes 
 1. Age-standardised rates are presented as a 4-year rolling block of data.  
 2. Deaths were derived by state and year of registration.  
 3. Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population.  
 4. Only Queensland, South Australia, Western Australia and the Northern Territory have  
 Indigenous death registration data considered to be of a publishable standard. 
 5. Bars on graphs represent 95% confidence intervals. 
 Source: AIHW Mortality Database. 
 Figure 19: Age-standardised cervical cancer mortality rates by Indigenous status, 
women aged 20–69 years (Queensland, Western Australia, South Australia and  
Northern Territory), 2000–2003 
 
 
  Indigenous  Other Australians
AS rate (A)  12.0 2.5
95% CI  7.5–18.0 2.1–2.8
 
• Owing to the difficulties of Indigenous identification in health data collections, only 
Indigenous mortality data from Queensland, Western Australia, South Australia and the 
Northern Territory are considered to be of publishable standard. Therefore, all cervical 
cancer mortality data for both Indigenous women and other Australian women used in 
this analysis are confined to these jurisdictions. 
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• The age-standardised mortality rate attributable to cervical cancer among Indigenous 
women in the target age group in the 2000–2003 period was 12.0 per 100,000 women and 
was considerably higher than the mortality rate for other Australian women in the same 
age range (2.5 per 100,000 women) (Table 28, page 68). 
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Tables 
Indicator 1: Participation  
Table 1a: Number of women participating in the National Cervical Screening Program by age, 
states and territories, 2000–2001 
Age group NSW Vic(a) Qld WA SA Tas ACT(a) NT Australia
20–24 98,410 81,673 62,480 33,698 25,410 8,804 6,193 4,595 321,263
25–29 143,840 114,693 79,515 43,183 32,306 10,127 7,845 5,898 437,407
30–34 153,836 125,139 81,104 46,448 36,257 10,994 8,158 5,827 467,763
35–39 154,920 121,537 80,964 47,090 37,436 11,924 7,976 5,043 466,890
40–44 140,924 112,399 74,268 43,390 35,941 11,193 7,474 4,188 429,777
45–49 118,907 95,793 62,383 36,619 30,829 9,475 6,708 3,464 364,178
50–54 99,838 82,150 52,047 29,221 26,386 8,081 6,059 2,509 306,291
55–59 68,905 56,506 35,118 18,729 18,311 5,505 3,665 1,375 208,114
60–64 50,567 42,868 24,336 14,060 14,155 4,106 2,378 766 153,236
65–69 35,430 31,124 16,749 9,621 10,236 2,974 1,519 359 108,012
70–74 14,641 10,486 8,042 3,641 6,495 798 483 149 44,735
75–79 5,341 3,617 3,098 1,173 0 327 168 53 13,777
80+ 2,190 1,584 1,354 542 0 133 46 26 5,875
Not stated 3,720 0 320 0 20 3 9 18 4,090
All ages 
20–80+ years 1,091,469 879,569 581,778 327,415 273,782 84,444 58,681 34,270 3,331,408
Target age 
20–69 years 1,065,577 863,882 568,964 322,059 267,267 83,183 57,975 34,024 3,262,931
(a) The Victorian and Australian Capital Territory registers only register women with a Victorian or Australian Capital Territory address 
respectively. 
Note: These numbers may be overestimated because of double counting of some women between some states. This may be the result of difficulty 
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident 
overseas; however, the likely impact of double counting is probably very small. 
Source: AIHW analysis of state and territory Cervical Cytology Registry data. 
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Table 1b: Proportion of women participating in the National Cervical Screening Program by age, 
states and territories, 2000–2001 
Age group NSW Vic(a) Qld WA(a) SA Tas ACT(a) NT Australia 
 (Per cent) 
20–24 46.4 51.1 51.0 53.0 54.8 62.7 47.8 59.9 50.3 
25–29 58.8 63.3 59.3 62.7 64.2 66.9 59.5 64.2 61.0 
30–34 63.7 67.2 61.2 65.9 68.6 68.5 64.9 65.9 64.9 
35–39 63.7 67.6 60.5 66.1 68.3 69.8 64.9 64.1 64.8 
40–44 62.9 68.0 59.9 64.8 68.5 67.5 64.6 63.1 64.4 
45–49 63.7 69.3 60.0 64.3 68.9 67.6 66.0 64.9 65.0 
50–54 61.7 68.1 57.1 61.7 65.8 65.8 68.5 61.9 63.0 
55–59 63.2 71.2 58.3 62.7 69.0 66.1 72.1 62.3 64.9 
60–64 52.9 61.1 48.8 54.9 60.7 55.2 63.2 55.5 55.3 
65–69 43.7 52.3 41.9 46.5 51.2 48.1 54.4 42.6 46.7 
70–74 18.1 17.7 20.8 18.9 31.3 13.4 19.0 24.7 19.7 
75–79 7.6 7.1 9.4 7.3 0.0 6.2 7.6 13.6 7.0 
80+ 2.4 2.4 3.1 2.5 0.0 1.9 1.8 5.5 2.3 
All ages 20–80+ years         
Crude rate 53.5 58.0 52.6 56.6 57.5 58.1 58.4 61.8 55.3 
AS rate 53.0 57.7 51.3 55.0 58.2 58.0 56.2 55.9 54.7 
95% CI 52.9–53.1 57.6–57.9 51.2–51.4 54.8–55.1 58.0–58.4 57.6–58.3 55.8–56.7 55.2–56.6 54.6–54.7 
Target age 20–69 years  
Crude rate 59.2 64.5 57.4 61.7 64.9 65.4 62.2 63.0 61.1 
AS rate 59.1 64.6 57.0 61.4 64.9 65.2 62.8 61.7 61.0 
95% CI 59.0–59.3 64.5–64.8 56.8–57.1 61.2–61.6 64.6–65.1 64.7–65.6 62.3–63.4 61.0–62.4 60.9–61.1 
(a) The Victorian and Australian Capital Territory registers only register women with a Victorian or Australian Capital Territory address 
respectively. 
Notes 
1. These numbers may be overestimated because of double counting of some women between some states. This may be the result of 
difficulty in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of 
women resident overseas; however, the likely impact of double counting is probably very small. 
2. Rates are standardised to the 2001 Australian total population. 
3. In 2001 the ABS carried out a full population Census and a national health survey. These led to the revision of the ABS estimated resident 
population (ERP) data, the introduction of a new Australian standard population for use in age standardisation and the production of new 
estimates of hysterectomy status among Australian women. The denominators for participation rates presented in this report have been 
calculated using the 2001 ABS National Health Survey hysterectomy fractions and the revised ERP values, and age-adjusted using the 
2001 Australian standard population. The denominators for the equivalent rates in previous reports were calculated using the 1995 ABS 
National Health Survey hysterectomy fractions and unrevised ERP values, and age-adjusted using the 1991 Australian standard 
population. The combined effect of these changes is that participation rates presented in this report are on average between 1 and 2 
percentage points lower than equivalent rates in previous reports. 
4. Separate rates cannot be calculated for women in the 80–84 and 85 and over age groups because hysterectomy fractions are not available 
for these age groups; however a hysterectomy fraction is available for women aged 80 and over. 
Source: AIHW analysis of state and territory Cervical Cytology Registry data. 
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Table 2a: Number of women participating in the National Cervical Screening Program by age, 
states and territories, 2002–2003 
Age group NSW Vic(a) Qld WA SA Tas ACT(a) NT Australia 
20–24 98,494 82,857 63,774 34,023 25,125 8,418 6,663 4,372 323,726 
25–29 132,156 105,856 74,072 39,544 29,565 8,765 7,504 5,184 402,646 
30–34 157,756 127,641 84,658 46,613 35,871 10,685 8,514 5,545 477,283 
35–39 147,609 119,391 79,945 45,241 35,799 10,576 7,700 4,747 451,008 
40–44 145,889 115,049 79,388 44,564 36,382 11,135 7,630 4,141 444,178 
45–49 123,071 99,382 66,638 38,070 31,814 9,411 6,735 3,445 378,566 
50–54 101,816 83,901 55,659 30,731 27,181 7,925 5,899 2,658 315,770 
55–59 79,023 65,444 42,487 21,741 21,483 6,320 4,254 1,643 242,395 
60–64 53,931 45,240 28,134 14,899 15,121 4,424 2,606 848 165,203 
65–69 38,299 33,330 19,224 10,430 11,111 3,140 1,630 415 117,579 
70–74 13,523 10,331 8,505 3,513 3,974 841 426 179 41,292 
75–79 4,695 3,487 3,114 1,095 1,521 269 114 48 14,343 
80+ 1,970 1,600 1,429 485 597 130 56 22 6,289 
Not stated 2,493 0 20 0 12 7 1 14 2,547 
All ages 
20–80+ years 1,100,725 893,509 607,047 330,949 275,556 82,046 59,732 33,261 3,382,825 
Target age 
20–69 years 1,078,044 878,091 593,979 325,856 269,452 80,799 59,135 32,998 3,318,354 
(a) The Victorian and Australian Capital Territory registers only register women with a Victorian or Australian Capital Territory address 
respectively. 
Note: These numbers may be overestimated because of double counting of some women between some states. This may be the result of difficulty 
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident 
overseas; however, the likely impact of double counting is probably very small 
Source: AIHW analysis of state and territory Cervical Cytology Registry data. 
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Table 2b: Proportion of women participating in the National Cervical Screening Program by age, 
states and territories, 2002–2003 
Age group NSW Vic(a) Qld WA(a) SA Tas ACT(a) NT Australia 
 (Per cent) 
20–24 45.3 49.8 49.9 51.7 52.9 59.3 49.5 59.4 49.0 
25–29 56.7 61.3 57.2 60.2 63.1 63.7 59.0 61.6 59.0 
30–34 62.2 65.8 59.9 64.1 67.4 66.0 65.4 61.3 63.4 
35–39 62.7 66.9 59.9 64.5 68.1 65.7 64.6 62.5 63.9 
40–44 62.8 67.3 60.2 64.4 68.1 65.7 65.2 60.6 64.1 
45–49 64.2 69.8 61.1 64.8 70.1 65.5 66.7 63.5 65.6 
50–54 61.6 68.0 58.5 61.6 67.2 63.1 65.8 61.1 63.1 
55–59 64.3 72.6 60.4 63.1 70.9 66.7 71.1 65.6 66.2 
60–64 54.2 62.0 51.2 54.0 62.7 56.3 63.4 51.2 56.4 
65–69 45.9 54.2 44.9 47.3 54.3 49.1 53.6 44.5 48.8 
70–74 17.0 17.8 21.7 17.9 19.9 14.1 16.8 26.9 18.3 
75–79 6.6 6.6 9.1 6.6 8.0 5.1 4.9 10.8 7.1 
80+ 2.0 2.6 3.0 2.0 2.2 1.7 1.9 4.2 2.2 
All ages 20–80+ years         
Crude rate 52.8 57.9 52.5 55.5 57.4 55.9 58.1 59.7 54.7 
AS rate 52.6 57.4 51.5 54.2 58.3 56.1 55.9 54.5 54.3 
95% CI 52.5–52.7 57.3–57.5 51.4–51.6 54.0–54.3 58.0–58.5 55.7–56.5 55.5–56.4 53.8–55.1 54.3–54.4 
Target age 20–69 years  
Crude rate 58.8 64.0 57.3 60.8 65.0 63.2 62.2 61.0 60.6 
AS rate 58.8 64.2 57.2 60.6 65.1 63.1 62.7 60.2 60.7 
95% CI 58.7–58.9 64.1–64.4 57.0–57.3 60.3–60.8 64.8–65.3 62.6–63.5 62.2–63.3 59.5–60.9 60.6–60.8 
(a) The Victorian and Australian Capital Territory registers only register women with a Victorian or Australian Capital Territory address 
 respectively. 
Notes 
1. These numbers may be overestimated because of double counting of some women between some states. This may be the result of 
difficulty in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of 
women resident overseas; however, the likely impact of double counting is probably very small 
2. Rates are standardised to the 2001 Australian total population. 
3. In 2001 the ABS carried out a full population Census and a national health survey. These led to the revision of the ABS estimated resident 
population (ERP) data, the introduction of a new Australian standard population for use in age standardisation and the production of new 
estimates of hysterectomy status among Australian women. The denominators for participation rates presented in this report have been 
calculated using the 2001 ABS National Health Survey hysterectomy fractions and the revised ERP values, and age-adjusted using the 
2001 Australian standard population. The denominators for the equivalent rates in previous reports were calculated using the 1995 ABS 
National Health Survey hysterectomy fractions and unrevised ERP values, and age-adjusted using the 1991 Australian standard population. 
The combined effect of these changes is that participation rates presented in this report are on average between 1 and 2 percentage points 
lower than equivalent rates in previous reports. 
4. Separate rates cannot be calculated for women in the 80–84 and 85 and over age groups because hysterectomy fractions are not available 
for these age groups; however a hysterectomy fraction is available for women aged 80 and over. 
Source: AIHW analysis of state and territory Cervical Cytology Registry data. 
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Indicator 2: Early re-screening 
Table 3: Number of women with repeat screenings in the 21 months following a negative Pap 
smear in the 2002 cohort, states and territories, and Australia 2001 and 2002 cohorts 
No. of tests NSW Vic(a) Qld WA SA Tas ACT(a) NT 
Australia 
2001 
cohort 
Australia
2002 
cohort 
 Number of women 
0 39,274 33,695 19,504 11,277 10,408 2,783 2,277 1,391 121,736 120,609 
1 13,392 12,494 5,995 3,863 2,714 816 681 379 43,594 40,334 
2 1,593 1,680 849 484 294 103 90 69 5,296 5,162 
3 244 451 209 60 42 15 21 9 1,092 1,051 
4 35 94 40 10 11 0 1 4 206 195 
5 or more 6 46 14 0 2 1 1 0 61 70 
(a) The Victorian and Australian Capital Territory registries only register women with a Victorian and Australian Capital Territory address 
respectively.  
Notes 
1. These numbers may be overestimated because of double counting of some women between some states. This may be the result of 
difficulty in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of 
women resident overseas; however, the likely impact of double counting is probably very small. 
2. The data for the 2001 cohort are not comparable with the data published in Cervical Screening in Australia 2001–2002 because Northern 
Territory data have been included in this report 
Source: State and territory Cervical Cytology Registry data. 
Table 4: Percentage of women with repeat screenings in the 21 months following a negative Pap 
smear in the 2002 cohort, states and territories, and Australia 2001 and 2002 cohorts 
No. of tests NSW Vic(a) Qld WA SA Tas ACT(a) NT 
Australia 
2001–2002 
Australia
2002–2003 
 Percent 
0 72.0 69.5 73.3 71.9 77.3 74.9 74.1 75.1 70.8 72.0 
1 24.6 25.8 22.5 24.6 20.1 21.9 22.2 20.5 25.3 24.1 
2 2.9 3.5 3.2 3.1 2.2 2.8 2.9 3.7 3.1 3.1 
3 0.4 0.9 0.8 0.4 0.3 0.4 0.7 0.5 0.6 0.6 
4 0.1 0.2 0.2 0.1 0.1 0.0 0.0 0.2 0.1 0.1 
5 or more 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
(a) The Victorian and Australian Capital Territory registries only register women with a Victorian and Australian Capital Territory address 
respectively.  
Notes 
1. These numbers may be overestimated because of double counting of some women between some states. This may be the result of 
difficulty in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of 
women resident overseas; however, the likely impact of double counting is probably very small. 
2. The data for the 2001 cohort are not comparable with the data published in Cervical Screening in Australia 2001–2002 because Northern 
Territory data have been included in this report 
Source: State and territory Cervical Cytology Registry data. 
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Indicator 3: Low-grade abnormality detection 
Table 5a: Number of low- and high-grade abnormalities on histology for women aged 20–69 years, 
states and territories, 2002  
Abnormalities NSW Vic Qld WA SA Tas ACT NT Australia 
Low-grade 6,477 3,015 4,273 2,661 1,205 473 332 345 18,781 
High-grade 5,034 3,301 3,056 1,647 952 417 253 243 14,903 
Ratio 1.29 0.91 1.40 1.62 1.27 1.13 1.31 1.42 1.26 
 Percentage of all screens in 2002 
Low-grade 1.1 0.6 1.3 1.4 0.8 1.1 1.0 1.8 1.0 
High-grade 0.8 0.7 1.0 0.9 0.6 0.9 0.8 1.2 0.8 
Notes 
1. These numbers may be overestimated because of double counting of some women between some states. This may be the result of 
difficulty in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of 
women resident overseas; however, the likely impact of double counting is probably very small. 
2. The Western Australian Registry has collated data for Indicator 3 according to the woman's age at time of biopsy result and selected 
the most abnormal result in the time period. This may result in discrepancies when comparing totals with Indicator 4 where the age is the 
woman’s age at the time of the Pap smear. 
Source: State and territory Cervical Cytology Registry data. 
 
 
 
Table 5b: Number of low- and high-grade abnormalities on histology for women aged 20–69 years, 
states and territories, 2003 
Abnormalities NSW Vic Qld WA SA Tas ACT NT Australia 
Low-grade 6,567 3,395 3,456 2,821 1,243 322 337 302 18,443 
High-grade 4,655 3,591 3,121 1,648 942 336 317 230 14,840 
Ratio 1.41 0.95 1.11 1.71 1.32 0.96 1.06 1.31 1.24 
 Percentage of all screens in 2003 
Low-grade 1.1 0.7 1.0 1.5 0.8 0.7 1.0 1.7 1.0 
High-grade 0.8 0.7 0.9 0.9 0.6 0.8 1.0 1.3 0.8 
Notes  
1. These numbers may be overestimated because of double counting of some women between some states. This may be the result of 
difficulty in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of 
women resident overseas; however, the likely impact of double counting is probably very small. 
2. The Western Australian Registry has collated data for Indicator 3 according to the woman's age at time of biopsy result and selected 
the most abnormal result in the time period. This may result in discrepancies when comparing totals with Indicator 4 where the age is the 
woman’s age at the time of the Pap smear. 
Source: State and territory Cervical Cytology Registry data. 
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Indicator 4: High-grade abnormality detection 
Table 6a: Rate of histologically confirmed high-grade abnormalities per 1,000 women screened  
by age, states and territories, 2002 
Age group NSW Vic Qld WA SA Tas ACT NT Australia 
20–24 21.0 17.2 19.7 18.4 13.5 24.0 15.8 25.7 18.9 
25–29 18.0 14.5 17.4 18.8 14.9 15.4 13.3 20.6 16.7 
30–34 11.2 9.5 14.4 12.0 9.7 13.6 12.5 13.6 11.3 
35–39 7.5 5.4 7.8 7.5 6.2 9.4 6.8 10.8 6.9 
40–44 4.9 4.0 6.0 4.8 3.4 7.3 4.9 6.2 4.8 
45–49 3.0 2.1 4.5 2.9 2.9 2.9 1.8 6.4 3.0 
50–54 1.9 1.3 2.6 2.7 1.6 3.5 2.7 3.3 2.0 
55–59 1.6 1.1 2.6 1.7 1.7 2.1 2.6 3.3 1.7 
60–64 1.2 0.8 2.2 1.6 1.2 0.9 1.4 0.0 1.3 
65–69 1.1 1.0 2.4 0.9 1.4 1.8 4.5 9.0 1.4 
70–74 2.4 2.1 3.3 2.5 3.1 8.4 4.0 0.0 2.7 
75–79 1.8 0.9 3.0 0.0 10.2 0.0 0.0 0.0 2.5 
80–84 3.5 0.0 8.8 5.7 4.0 0.0 47.6 0.0 4.2 
85+ 3.5 0.0 30.6 11.6 55.6 0.0 0.0 0.0 13.5 
All ages 
20–85+ years 8.1 6.5 9.4 8.4 6.3 9.2 7.6 12.5 7.8 
Target age 
20–69 years 8.2 6.6 9.5 8.5 6.3 9.3 7.6 12.6 7.9 
Note: These numbers may overestimated because of double counting of some women between some states. This may be the result of  
difficulty in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of  
women resident overseas; however, the likely impact of double counting is probably very small. 
Source: State and territory Cervical Cytology Registry data. 
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Table 6b: Rate of histologically confirmed high-grade abnormalities per 1,000 women screened by 
age, states and territories, 2003 
Age group NSW Vic Qld WA SA Tas ACT NT Australia 
20–24 18.4 18.7 20.1 17.6 12.6 22.0 19.4 29.1 18.5 
25–29 16.6 16.4 17.6 19.7 13.5 14.9 18.5 21.3 16.9 
30–34 10.5 10.2 13.0 11.7 9.9 8.8 12.5 13.8 11.0 
35–39 6.2 6.3 8.6 7.0 6.5 7.8 8.2 10.5 6.9 
40–44 4.2 4.6 6.4 5.6 5.0 5.4 4.7 7.5 5.0 
45–49 3.2 2.7 3.7 2.6 3.4 3.4 6.2 3.8 3.2 
50–54 1.8 1.4 2.4 1.9 2.0 1.6 2.4 2.8 1.8 
55–59 1.4 1.1 1.8 1.5 1.5 1.9 4.7 0.0 1.5 
60–64 1.6 1.0 1.9 1.7 1.7 0.4 6.5 6.8 1.6 
65–69 1.6 1.1 1.7 1.5 0.3 1.2 6.9 4.4 1.4 
70–74 1.2 1.1 2.3 2.1 3.0 2.2 4.8 0.0 1.7 
75–79 3.7 1.6 4.4 1.7 5.4 0.0 31.3 0.0 3.5 
80–84 3.4 0.0 9.3 5.6 19.6 0.0 0.0 0.0 5.2 
85+ 6.2 7.8 9.4 0.0 38.5 0.0 0.0 0.0 9.2 
All ages 
20–85+ years 7.4 7.2 9.0 8.2 6.3 7.4 9.8 12.7 7.7 
Target age 
20–69 years 7.6 7.3 9.1 8.3 6.3 7.5 9.8 12.8 7.8 
Note: These numbers may be overestimated because of double counting of some women between some states. This may be the result of difficulty 
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident 
overseas; however, the likely impact of double counting is probably very small. 
Source: State and territory Cervical Cytology Registry data. 
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Table 7a: Number of histologically confirmed high-grade abnormalities by age, states and 
territories, 2002 
Age group NSW Vic Qld WA SA Tas ACT NT Australia 
20–24 1,152 806 680 358 192 113 58 66 3,425 
25–29 1,378 894 760 434 254 78 57 65 3,920 
30–34 1,004 705 664 322 198 82 59 44 3,078 
35–39 640 375 352 194 127 56 30 30 1,804 
40–44 406 262 254 122 69 46 21 15 1,195 
45–49 211 122 161 62 51 15 7 13 642 
50–54 113 60 79 47 24 15 9 5 352 
55–59 72 38 53 20 19 7 6 3 218 
60–64 35 21 30 13 10 2 2 0 113 
65–69 23 18 23 5 8 3 4 2 86 
70–74 19 13 15 5 7 4 1 0 64 
75–79 5 2 5 0 9 0 0 0 21 
80–84 3 0 5 1 1 0 1 0 11 
85+ 1 0 6 1 5 0 0 0 13 
Age not stated 0 0 1 0 0 0 0 0 1 
All ages 
20–85+ years 5,062 3,316 3,088 1,584 974 421 255 243 14,943 
Target age 
20–69 years 5,034 3,301 3,056 1,577 952 417 253 243 14,833 
Notes 
1. These numbers may overestimated because of double counting of some women between some states. This may be the result of difficulty in 
identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women 
resident overseas; however, the likely impact of double counting is probably very small. 
2.  The Western Australian Registry has collated data for Indicator 4 according to the woman's age at time of first smear result in the time 
period. In the event there is no smear in the time period, the age is calculated according to the age at time of first result categorised as most 
abnormal biopsy in the time period. This may result in discrepancies when comparing totals with Indicator 3. 
Source: State and territory Cervical Cytology Registry data. 
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Table 7b: Number of histologically confirmed high-grade abnormalities by age, states and 
territories, 2003 
Age group NSW Vic Qld WA SA Tas ACT NT Australia 
20–24 1,017 865 739 342 174 100 72 70 3,379 
25–29 1,349 961 737 441 220 71 75 59 3,913 
30–34 937 737 641 315 193 52 59 42 2,976 
35–39 550 420 395 179 124 45 34 27 1,774 
40–44 342 301 295 143 99 33 20 17 1,250 
45–49 218 151 143 57 63 18 23 7 680 
50–54 104 67 76 34 32 7 8 4 332 
55–59 58 43 45 19 19 7 11 0 202 
60–64 48 26 31 14 15 1 9 3 147 
65–69 32 20 19 9 3 2 6 1 92 
70–74 10 6 10 4 6 1 1 0 38 
75–79 11 3 7 1 4 0 2 0 28 
80–84 3 0 5 1 4 0 0 0 13 
85+ 2 2 2 0 3 0 0 0 9 
Age not stated 0 0 0 0 0 0 0 0 0 
All ages 
20–85+ years 4,681 3,602 3,145 1,559 959 337 320 230 14,833 
Target age 
20–69 years 4,655 3,591 3,121 1,553 942 336 317 230 14,745 
Notes 
1. These numbers may be overestimated because of double counting of some women between some states. This may be the result of 
difficulty in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of 
women resident overseas; however, the likely impact of double counting is probably very small. 
2.  The Western Australian Registry has collated data for Indicator 4 according to the woman's age at time of first smear result in the time 
period. In the event there is no smear in the time period, the age is calculated according to the age at time of first result categorised as most 
abnormal biopsy in the time period. This may result in discrepancies when comparing totals with Indicator 3. 
Source: State and territory Cervical Cytology Registry data. 
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Table 8a: Number of women screened by age, states and territories, 2002 
Age group NSW Vic Qld WA SA Tas ACT NT Australia 
20–24 54,880 46,923 34,551 19,450 14,198 4,715 3,676 2,568 180,961 
25–29 76,499 61,866 43,714 23,061 17,059 5,055 4,278 3,156 234,688 
30–34 89,887 74,403 46,004 26,730 20,357 6,046 4,727 3,245 271,399 
35–39 85,841 69,551 45,033 26,005 20,480 5,976 4,427 2,784 260,097 
40–44 83,130 65,928 42,340 25,315 20,270 6,269 4,288 2,418 249,958 
45–49 69,803 56,897 35,401 21,614 17,643 5,201 3,790 2,023 212,372 
50–54 58,172 47,711 29,858 17,274 14,825 4,336 3,280 1,493 176,949 
55–59 43,921 35,963 20,348 11,916 11,371 3,346 2,335 907 130,107 
60–64 30,177 25,118 13,923 8,079 8,053 2,343 1,447 485 89,625 
65–69 20,961 17,777 9,555 5,535 5,849 1,655 885 221 62,438 
70–74 7,840 6,280 4,572 1,977 2,242 478 250 92 23,731 
75–79 2,770 2,181 1,665 619 880 151 57 26 8,349 
80–84 866 705 566 176 248 51 21 9 2,642 
85+ 287 284 196 86 90 17 4 1 965 
Age not stated 1,687 0 147 0 14 4 0 5 1,857 
All ages 
20–85+ years 626,721 511,587 327,873 187,837 153,579 45,643 33,465 19,433 1,906,138 
Target age 
20–69 years 613,271 502,137 320,727 184,979 150,105 44,942 33,133 19,300 1,868,594 
Note: These numbers may be overestimated because of double counting of some women between some states. This may be the result of difficulty 
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident 
overseas; however, the likely impact of double counting is probably very small. 
Source: State and territory Cervical Cytology Registry data. 
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Table 8b: Number of women screened by age, states and territory, 2003 
Age group NSW Vic Qld WA SA Tas ACT NT Australia 
20–24 55,354 46,191 36,771 19,483 13,801 4,555 3,711 2,398 182,264 
25–29 81,077 58,604 41,976 22,387 16,091 4,755 4,061 2,762 231,713 
30–34 89,266 71,966 49,221 26,823 19,532 5,897 4,727 3,060 270,492 
35–39 88,253 66,669 45,697 25,728 19,213 5,767 4,141 2,572 258,040 
40–44 81,964 64,992 46,086 25,631 19,883 6,066 4,237 2,254 251,113 
45–49 69,169 56,132 38,788 22,034 17,324 5,292 3,730 1,855 214,324 
50–54 58,634 47,650 32,050 17,726 14,947 4,438 3,279 1,438 180,162 
55–59 40,689 37,996 24,995 12,690 11,842 3,616 2,352 882 135,062 
60–64 29,460 25,393 16,183 8,452 8,249 2,484 1,382 444 92,047 
65–69 20,399 18,903 11,040 5,883 5,964 1,736 870 228 65,023 
70–74 8,286 5,455 4,421 1,884 1,982 447 210 96 22,781 
75–79 2,950 1,883 1,594 579 738 137 64 26 7,971 
80–84 890 616 536 177 208 52 26 9 2,514 
85+ 324 256 212 80 79 12 7 4 974 
Age not stated 1,822 0 0 0 3 6 1 9 1,841 
All ages 
20–85+ years 628,537 502,706 349,570 189,557 149,856 45,260 32,798 18,037 1,916,321 
Target age 
20–69 years 614,265 494,496 342,807 186,837 146,846 44,606 32,490 17,893 1,880,240 
Note: These numbers may be overestimated because of double counting of some women between some states. This may be the result of difficulty 
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident 
overseas; however, the likely impact of double counting is probably very small. 
Source: State and territory Cervical Cytology Registry data. 
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 Table 9a: Age-standardised high-grade abnormality rate on histology, per 1,000 women screened 
aged 20–69 years, states and territories, 2002 
 NSW Vic Qld WA SA Tas ACT NT Australia 
All ages 
20–85+ years                   
AS rate 7.2 5.6 8.7 7.4 7.1 8.2 7.5 9.3 7.1 
95% CI 7.0–7.5 5.4–5.8 8.1–9.3 6.8–8.0 6.1–8.2 7.4–9.1 5.3–10.0 8.0–10.6 7.0–7.3 
Target age 
20–69 years                   
AS rate 7.9 6.3 8.7 7.9 6.2 8.9 7.1 10.6 7.5 
95% CI 7.7–8.1 6.1–6.5 8.4–9.0 7.5–8.3 5.8–6.6 8.1–9.8 6.3–8.1 9.1–12.1 7.4–7.6 
Notes 
1. Rates are standardised to the 2001 Australian total population. 
2. These numbers may be overestimated because of double counting of some women between some states. This may be the result of difficulty 
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women 
resident overseas; however, the likely impact of double counting is probably very small. 
Source: AIHW analysis of state and territory Cervical Cytology Registry data. 
 
 
Table 9b: Age-standardised high-grade abnormality rate on histology, per 1,000 women screened 
aged 20–69 years, states and territories, 2003 
 NSW Vic Qld WA SA Tas ACT NT Australia 
All ages 
20–85+ years                   
AS rate 6.7 6.4 8.1 7.1 7.0 6.6 9.5 9.4 7.0 
95% CI 6.4–7.0 6.1–6.7 7.7–8.6 6.7–7.6 6.0–8.1 5.9–7.4 7.7–11.5 8.1–10.8 6.9–7.2 
Target age 
20–69 years                   
AS rate 7.2 7.1 8.5 7.8 6.3 7.5 9.3 10.7 7.5 
95% CI 7.0–7.4 6.8–7.3 8.2–8.8 7.4–8.2 5.9–6.7 6.7–8.3 8.3–10.5 9.3–12.3 7.4–7.6 
Notes  
1. Rates are standardised to the 2001 Australian total population. 
2. These numbers may be overestimated because of double counting of some women between some states. This may be the result of difficulty 
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women 
resident overseas; however, the likely impact of double counting is probably very small. 
Source: AIHW analysis of state and territory Cervical Cytology Registry data. 
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Indicator 5.1: Incidence of micro-invasive cervical cancer 
Table 10: New cases of micro-invasive cervical cancer by age, Australia, 1990–2001 
Age group 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001
0–4 0 0 0 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 0 0 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0 0 0 0
15–19 0 1 0 0 0 0 1 0 0 0 0 0
20–24 4  0 5 1 7 1 6 3 2 2 1 2
25–29 14 14 14 9 17 17 18 10 18 14 12 12
30–34 32 31 32 32 36 42 18 27 18 14 25 22
35–39 25 40 25 26 30 29 35 22 26 21 14 15
40–44 26 30 24 17 25 30 23 22 22 15 8 6
45–49 19 9 13 15 26 23 12 11 16 7 16 15
50–54 6 11 12 17 9 12 11 8 13 7 6 9
55–59 8 7 12 5 5 9 7 8 3 8 4 4
60–64 8 7 8 7 10 11 6 6 5 2 3 4
65–69 6 7 9 10 6 7 10 2 2 3 0 2
70–74 2 4 2 4 6 5 4 4 3 2 0 2
75–79 3 3 2 1 3 5 2 2 2 1 1 3
80–84 0 2 0 0 0 1 1 0 2 0 2 0
85+ 0 0 0 1 2 1 1 0 0 0 0 2
All ages 
0–85+ years 153 166 158 145 182 193 155 125 132 96 92 98
Target age 
20–69 years 148 156 154 139 171 181 146 119 125 93 89 91
Note: Cancer incidence estimates provided in this publication were made in March 2005. These estimates may be updated at any time as case 
details are added, modified or deleted in the national database. These modifications may occur several years after the initial diagnosis as 
additional case details are received by the state and territory cancer registries from data suppliers and then passed to the NCSCH. This may have 
the impact of making incidence estimates for the same year incompatible between publications, but for the most part these changes are very 
small. 
Source: National Cancer Statistics Clearing House (AIHW). 
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Table 11: Age-specific and age-standardised incidence rates of micro-invasive cervical cancer by 
age, Australia, 1990–2001 
Age group 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0
20–24 0.6 0.0 0.7 0.1 1.0 0.1 0.9 0.4 0.3 0.3 0.2 0.3
25–29 2.0 2.0 2.0 1.3 2.5 2.5 2.5 1.4 2.5 1.9 1.7 1.7
30–34 4.6 4.4 4.4 4.4 4.9 5.7 2.5 3.8 2.5 2.0 3.5 3.0
35–39 3.8 6.0 3.7 3.8 4.3 4.1 4.8 3.0 3.5 2.8 1.9 2.0
40–44 4.2 4.7 3.7 2.6 3.8 4.5 3.4 3.2 3.1 2.1 1.1 0.8
45–49 4.0 1.8 2.4 2.6 4.4 3.7 1.9 1.7 2.4 1.1 2.4 2.2
50–54 1.5 2.7 2.8 3.9 2.0 2.5 2.2 1.5 2.3 1.2 1.0 1.4
55–59 2.2 2.0 3.3 1.3 1.3 2.3 1.7 1.9 0.7 1.8 0.8 0.8
60–64 2.2 1.9 2.2 1.9 2.8 3.1 1.7 1.7 1.3 0.5 0.8 1.0
65–69 1.7 2.0 2.5 2.8 1.7 2.0 2.8 0.6 0.6 0.9 0.0 0.6
70–74 0.7 1.4 0.7 1.3 1.9 1.5 1.2 1.2 0.9 0.6 0.0 0.6
75–79 1.4 1.3 0.9 0.4 1.3 2.1 0.8 0.8 0.7 0.4 0.3 1.0
80–84 0.0 1.4 0.0 0.0 0.0 0.6 0.6 0.0 1.1 0.0 1.1 0.0
85+ 0.0 0.0 0.0 0.8 1.6 0.7 0.7 0.0 0.0 0.0 0.0 1.1
All ages 0–85+ years                     
Crude rate 1.8 1.9 1.8 1.6 2.0 2.1 1.7 1.3 1.4 1.0 1.0 1.0
AS rate (A) 1.9 2.0 1.9 1.7 2.0 2.2 1.7 1.4 1.4 1.0 1.0 1.0
95% CI 1.6–2.2 1.7–2.3 1.6–2.2 1.4–2.0 1.8–2.4 1.9–2.5 1.4–2.0 1.1–1.6 1.2–1.7 0.8–1.2 0.8–1.2 0.8–1.2
AS rate (W) 1.7 1.8 1.7 1.5 1.9 1.9 1.5 1.2 1.3 0.9 0.9 0.9
95% CI 1.4–2.0 1.5–2.1 1.4–2.0 1.3–1.8 1.6–2.2 1.7–2.2 1.3–1.8 1.0–1.5 1.1–1.5 0.8–1.1 0.7–1.1 0.7–1.1
Target age 20–69 years                     
Crude rate 2.8 2.9 2.8 2.5 3.0 3.2 2.5 2.0 2.1 1.5 1.5 1.5
AS rate (A) 2.8 2.9 2.8 2.6 3.0 3.2 2.5 2.0 2.1 1.5 1.5 1.5
95% CI 2.4–3.3 2.5–3.4 2.4–3.3 2.1–3.0 2.6–3.5 2.7–3.7 2.1–3.0 1.7–2.4 1.7–2.5 1.2–1.9 1.2–1.8 1.2–1.8
AS rate (W) 2.8 2.8 2.8 2.5 3.0 3.1 2.5 2.0 2.1 1.5 1.5 1.5
95% CI 2.3–3.2 2.4–3.3 2.4–3.3 2.1–2.9 2.6–3.5 2.7–3.6 2.1–2.9 1.7–2.4 1.7–2.4 1.2–1.9 1.2–1.8 1.2–1.8
Note: Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population (A) and the WHO World Standard 
Population (W). 
Source: National Cancer Statistics Clearing House (AIHW). 
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Indicator 5.2: Incidence of invasive squamous, adenocarcinoma, 
adenosquamous and other cervical cancer 
Table 12: New cases of cervical cancer by age, Australia, 1990–2001 
Age group 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001
0–4 0 0 0 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 1 0 0 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0 0 0 0
15–19 1 1 0 1 1 2 1 1 2 0 2 2
20–24 13 12 10 10 16 4 15 10 10 8 7 7
25–29 59 48 54 38 49 53 45 44 48 57 40 41
30–34 114 120 109 105 123 113 68 79 83 74 84 59
35–39 156 140 126 129 132 111 142 102 102 101 70 88
40–44 140 150 130 128 133 118 117 103 101 104 81 67
45–49 121 104 101 102 132 98 103 78 111 77 75 101
50–54 69 87 78 90 86 58 81 76 65 67 59 78
55–59 80 63 78 78 73 69 63 51 52 49 56 53
60–64 78 80 75 76 88 71 61 53 56 64 62 47
65–69 76 89 89 92 95 78 65 58 54 54 52 43
70–74 67 79 72 64 79 69 62 45 59 47 57 42
75–79 51 48 52 46 66 51 51 45 44 40 50 39
80–84 29 35 34 37 40 30 41 32 39 33 36 40
85+ 24 33 22 21 22 33 25 28 29 19 23 28
All ages 
0–85+ years 1,078 1,089 1030 1017 1136 958 940 805 855 794 754 735
Target age 
20–69 years 906 893 850 848 927 773 760 654 682 655 586 584
Notes  
1. The table includes the incidence of micro-invasive and invasive cervical cancers. 
2. Cancer incidence estimates provided in this publication were made in March 2005. These estimates may be updated at any time as case 
details are added, modified or deleted in the national database. These modifications may occur several years after the initial diagnosis as 
additional case details are received by the state and territory cancer registries from data suppliers and then passed to the NCSCH. This may 
have the impact of making incidence estimates for the same year incompatible between publications, but for the most part these changes are 
very small. 
Source: National Cancer Statistics Clearing House (AIHW). 
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Table 13: Age-specific and age-standardised incidence rates of cervical cancer by age, Australia, 
1990–2001 
Age group 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.1 0.2 0.0 0.2 0.2 0.3 0.2 0.2 0.3 0.0 0.3 0.3
20–24 1.9 1.7 1.4 1.4 2.3 0.6 2.2 1.5 1.5 1.2 1.1 1.1
25–29 8.3 6.9 7.8 5.6 7.2 7.7 6.4 6.1 6.5 7.8 5.5 5.8
30–34 16.4 16.9 15.0 14.4 16.7 15.5 9.4 11.0 11.7 10.4 11.7 8.0
35–39 23.8 21.1 18.6 18.7 18.9 15.6 19.5 13.7 13.6 13.3 9.3 11.7
40–44 22.6 23.5 20.3 19.8 20.2 17.7 17.2 14.9 14.4 14.6 11.1 9.0
45–49 25.3 20.7 18.8 17.8 22.2 15.9 16.1 12.1 17.0 11.6 11.1 14.8
50–54 17.2 21.1 18.4 20.7 19.0 12.2 16.3 14.1 11.4 11.2 9.5 12.0
55–59 22.3 17.6 21.3 20.8 18.9 17.4 15.5 12.1 12.0 10.8 11.8 10.7
60–64 21.0 21.6 20.5 21.1 24.7 19.9 17.1 14.6 15.0 16.7 15.6 11.5
65–69 21.8 25.3 25.2 25.9 26.8 22.0 18.3 16.5 15.5 15.6 15.1 12.4
70–74 24.8 28.0 24.6 21.1 24.9 21.4 19.0 13.7 17.8 14.1 17.1 12.5
75–79 23.1 21.3 22.7 20.0 29.0 21.9 20.9 17.5 16.4 14.2 17.4 13.4
80–84 20.8 24.1 22.5 23.4 23.9 17.4 23.2 17.8 21.4 18.0 18.9 19.8
85+ 22.7 30.0 19.0 17.2 17.3 24.6 17.7 18.7 18.5 11.4 13.1 15.3
All ages 0–85+ years                 
Crude rate 12.6 12.6 11.7 11.5 12.7 10.6 10.2 8.6 9.1 8.3 7.8 7.5
AS rate (A) 13.4 13.2 12.2 11.9 13.0 10.7 10.3 8.7 9.0 8.3 7.7 7.3
AS rate (W) 11.4 11.1 10.4 10.1 11.0 9.1 8.7 7.3 7.6 7.1 6.5 6.2
Target age 20–69 years           
Crude rate 17.1 16.5 15.5 15.3 16.5 13.6 13.1 11.2 11.5 10.9 9.6 9.5
AS rate (A) 17.7 17.1 16.0 15.8 16.9 13.8 13.4 11.3 11.6 10.9 9.7 9.5
AS rate (W) 16.9 16.2 15.2 14.9 16.0 13.2 12.7 10.8 11.1 10.5 9.2 9.0
Notes: Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population (A) and the WHO World Standard  
Population (W). 
Source: National Cancer Statistics Clearing House (AIHW). 
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Table 14a: New cases of cervical cancer by age, states and territories, 1994–1997 
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 1 0 0 0 1
10–14 0 0 0 0 0 0 0 0 0
15–19 3 0 2 0 0 0 0 0 5
20–24 10 11 18 3  0 3  0 0  45
25–29 51 46 45 21 16 5 4 3 191
30–34 134 90 79 32 25 16 4 3 383
35–39 165 114 110 39 29 12 7 11 487
40–44 142 138 83 54 28 9 11 6 471
45–49 151 97 80 37 26 10 5 5 411
50–54 116 74 61 22 12 5 5 6 301
55–59 90 63 46 27 14 7 7 2 256
60–64 90 79 38 31 18 11 2 4 273
65–69 105 73 58 30 18 8 1 3 296
70–74 96 56 46 25 20 7 3 2 255
75–79 69 65 41 13 15 8 0  2 213
80–84 44 45 19 15 11 4 5 0  143
85+ 37 34 19 12 5 1  0 0  108
All ages 
0–85+ years 1,303 985 745 361 238 106 54 47 3,839
Target age 
20–69 years 1,054 785 618 296 186 86 46 43 3,114
Source: National Cancer Statistics Clearing House (AIHW). 
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Table 14b: Age-specific and age-standardised incidence rates of cervical cancer, states and 
territories, 1994–1997 
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.4 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.2
20–24 1.1 1.6 3.4 1.1 0.0 4.5 0.0 0.0 1.6
25–29 5.4 6.4 8.9 7.8 7.5 7.5 7.7 8.3 6.8
30–34 13.6 12.3 15.2 11.4 10.9 21.9 7.7 9.0 13.2
35–39 17.0 15.8 21.3 13.7 12.5 15.9 13.5 36.5 16.9
40–44 15.7 20.5 17.2 20.0 12.8 12.9 21.8 22.9 17.5
45–49 18.1 15.5 17.7 15.4 12.6 15.5 10.5 23.1 16.5
50–54 17.3 15.0 17.1 12.1 7.3 9.7 15.0 40.8 15.3
55–59 16.1 15.3 16.4 18.3 10.3 16.1 30.2 22.0 15.9
60–64 17.8 21.2 15.7 24.5 14.4 28.1 11.4 66.0 19.0
65–69 20.8 19.9 24.5 25.3 13.9 21.0 6.4 70.6 20.9
70–74 20.6 16.6 21.6 24.1 16.2 19.6 21.3 69.1 19.7
75–79 19.9 26.3 25.5 17.0 16.3 29.2 0.0 107.2 22.2
80–84 17.7 24.7 16.7 25.9 16.4 20.2 79.9 0.0 20.5
85+ 19.1 22.8 21.3 25.6 9.3 6.8 0.0 0.0 19.5
All ages 0–85+ years            
Crude rate 10.5 10.7 11.3 10.4 8.0 11.1 8.8 13.8 10.5
AS rate (A) 10.5 10.7 11.7 10.9 7.7 11.1 9.9 21.7 10.7
95% CI 10.0–11.1 10.1–11.4 10.9–12.6 9.8–12.1 6.8–8.8 9.1–13.4 7.4–13.0 14.8–30.4 10.3–11.0
AS rate (W) 8.9 9.0 10.0 9.1 6.6 9.6 8.2 17.8 9.0
95% CI 8.4–9.4 8.4–9.6 9.3–10.8 8.2–10.1 5.8–7.5 7.8–11.6 6.2–10.8 12.5–24.3 8.7–9.3
Target age 20–69 years            
Crude rate 13.5 13.5 15.0 13.5 10.0 14.6 11.5 20.1 13.6
AS rate (A) 13.8 13.8 15.3 13.9 9.9 14.5 12.4 26.2 13.8
95% CI 13.0–14.6 12.9–14.8 14.1–16.6 12.4–15.6 8.6–11.5 11.6–17.9 9.0–16.6 18.1–36.3 13.3–14.3
AS rate (W) 13.0 13.1 14.7 13.2 9.5 14.1 11.7 24.3 13.1
95% CI 12.3–13.9 12.2–14.0 13.6–15.9 11.7–14.8 8.2–11.0 11.3–17.4 8.5–15.7 16.9–33.5 12.7–13.6
Note: Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population (A) and the WHO World Standard  
Population (W). 
Source: National Cancer Statistics Clearing House (AIHW). 
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Table 15a: Number of new cases of cervical cancer by age, states and territories, 1998–2001 
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0
15–19 3 1 1 1 0 0 0 0 6
20–24 15 4 8 3 0 2 0 0 32
25–29 58 34 45 18 13 8 7 3 186
30–34 105 57 64 36 25 8 4 1 300
35–39 122 69 86 28 25 17 8 6 361
40–44 109 74 92 43 23 6 2 4 353
45–49 132 77 67 46 25 8 3 6 364
50–54 106 49 53 27 19 7 3 5 269
55–59 73 51 40 17 14 9 2 4 210
60–64 77 57 53 17 21 3 0  1 229
65–69 78 46 36 22 11 5 3 2 203
70–74 81 48 32 25 12 4 3 0 205
75–79 66 42 28 16 15 2 2 2 173
80–84 53 43 21 19 11 1 0 0 148
85+ 35 29 14 11 7 2 1 0 99
All ages 
0–85+ years 1,113 681 640 329 221 82 38 34 3,138
Target age 
20–69 years 875 518 544 257 176 73 32 32 2,507
Source: National Cancer Statistics Clearing House (AIHW). 
 55 
 
Table 15b: Age-specific and age-standardised incidence rates of cervical cancer, states and 
territories, 1998–2001 
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.4 0.2 0.2 0.4 0.0 0.0 0.0 0.0 0.2
20–24 1.8 0.6 1.6 1.2 0.0 3.5 0.0 0.0 1.2
25–29 5.9 4.6 8.3 6.4 6.3 12.7 13.2 8.0 6.4
30–34 10.9 7.7 12.2 12.8 11.7 12.2 7.9 2.9 10.4
35–39 12.0 9.2 15.4 9.4 10.7 23.1 15.5 18.4 12.0
40–44 11.2 10.3 17.3 14.8 10.1 8.3 4.0 13.9 12.2
45–49 14.8 11.6 13.5 17.1 11.6 11.9 6.1 23.9 13.6
50–54 13.0 8.1 11.6 11.5 9.4 11.3 6.8 25.2 11.0
55–59 11.5 11.0 11.6 9.8 9.1 18.5 6.9 32.2 11.3
60–64 14.2 14.3 19.2 11.9 15.9 7.2 0.0 13.3 14.7
65–69 16.0 12.8 15.1 18.0 9.1 13.4 18.4 41.3 14.6
70–74 17.1 13.8 14.2 22.5 9.8 11.4 20.2 0.0 15.4
75–79 16.4 14.3 14.8 17.4 13.9 6.5 16.0 89.2 15.3
80–84 19.5 22.2 16.4 31.0 15.2 4.7 0.0 0.0 19.6
85+ 14.6 16.1 12.5 18.8 10.6 11.1 16.4 0.0 14.5
All ages 0–85+ years             
Crude rate 8.6 7.1 9.0 8.9 7.3 8.6 6.0 9.2 8.2
AS rate (A) 8.4 6.9 9.1 9.0 6.9 8.6 6.3 12.7 8.1
95% CI 7.9–8.9 6.4–7.4 8.4–9.9 8.0–10.0 6.0–7.9 6.8–10.7 4.4–8.6 8.1–18.7 7.8–8.3
AS rate (W) 7.1 5.7 7.9 7.5 5.9 7.7 5.4 10.4 6.8
95% CI 6.7–7.5 5.3–6.2 7.3–8.5 6.7–8.4 5.1–6.8 6.1–9.6 3.8–7.4 6.9–15.0 6.6–7.1
Target age 20–69 years                
Crude rate 10.7 8.5 12.2 10.9 9.3 12.4 7.7 13.6 10.4
AS rate (A) 10.7 8.6 12.3 11.0 9.2 12.3 7.8 16.3 10.4
95% CI 10.0–11.5 7.9–9.3 11.3–13.4 9.7–12.4 7.9–10.7 9.7–15.5 5.3–11.0 10.7–23.5 10.0–10.8
AS rate (W) 10.2 8.1 11.8 10.5 8.8 12.1 7.7 15.1 9.9
95% CI 9.6–10.9 7.5–8.9 10.8–12.8 9.2–11.8 7.5–10.2 9.4–15.2 5.2–10.8 10.0–21.7 9.5–10.3
Note: Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population (A) and the WHO World Standard  
Population (W). 
Source: National Cancer Statistics Clearing House (AIHW). 
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Table 16a: New cases of cervical cancer by histological type for women aged 20–69 years, Australia, 
1990–2001 
Histological type 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001
Squamous 633 633 601 590 618 539 527 447 476 459 391 393
Adenocarcinoma 149 144 142 142 193 148 149 129 140 130 119 116
Adenosquamous 50 42 51 47 40 34 40 33 30 23 30 30
Other 74 74 56 69 76 52 44 45 36 43 46 45
Total 906 893 850 848 927 773 760 654 682 655 586 584
Micro-invasive 148 156 154 139 171 181 146 119 125 93 89 91
Source: National Cancer Statistics Clearing House (AIHW). 
 
 
 
Table 16b: Age-standardised incidence rates for cervical cancer by histological type for women 
aged 20–69 years, Australia, 1990–2001 
Histological type 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001
Squamous 12.4 12.2 11.3 11.1 11.3 9.6 9.3 7.8 8.1 7.7 6.5 6.4
Adenocarcinoma 2.9 2.8 2.7 2.6 3.5 2.6 2.6 2.2 2.4 2.2 2.0 1.9
Adenosquamous 1.0 0.8 1.0 0.9 0.7 0.6 0.7 0.6 0.5 0.4 0.5 0.5
Other 1.5 1.4 1.0 1.2 1.4 0.9 0.8 0.8 0.6 0.7 0.8 0.7
Micro-invasive 2.8 2.9 2.8 2.6 3.0 3.2 2.5 2.0 2.1 1.5 1.5 1.5
Note: Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population. 
Source: National Cancer Statistics Clearing House (AIHW). 
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Table 17a: New cases of cervical cancer by histological type for women, all ages 0–85+ years, 
Australia, 1990–2001 
Histological type 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001
Squamous 760 774 740 696 767 664 667 542 597 565 511 497
Adenocarcinoma 172 172 158 164 223 173 169 159 165 148 138 138
Adenosquamous 56 49 56 56 50 39 47 39 35 25 31 34
Other 90 94 76 101 96 82 57 65 58 56 74 66
Total 1,078 1,089 1,030 1,017 1,136 958 940 805 855 794 754 735
Micro-invasive 153 166 158 145 182 193 155 125 132 96 92 98
Source: National Cancer Statistics Clearing House (AIHW). 
 
 
 
Table 17b: Age-standardised incidence rates for cervical cancer by histological type for women, all 
ages 0–85+ years, Australia, 1990–2001 
Histological type 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001
Squamous 9.4 9.4 8.8 8.2 8.8 7.4 7.3 5.9 6.3 5.9 5.2 5.0
Adenocarcinoma 2.1 2.1 1.9 1.9 2.5 1.9 1.9 1.7 1.8 1.5 1.4 1.4
Adenosquamous 0.7 0.6 0.7 0.6 0.6 0.4 0.5 0.4 0.4 0.3 0.3 0.3
Other 1.1 1.1 0.9 1.1 1.1 0.9 0.6 0.7 0.6 0.6 0.7 0.6
Micro-invasive 1.9 2.0 1.9 1.7 2.0 2.2 1.7 1.4 1.4 1.0 1.0 1.0
Note: Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population. 
Source: National Cancer Statistics Clearing House (AIHW). 
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Indicator 5.3: Incidence by location 
Table 18: New cases of cervical cancer by age and location, 1994–1997 and 1998–2001 
 Major cities  Regional  Remote 
Age group 1994–1997 1998–2001 1994–1997 1998–2001 1994–1997 1998–2001 
0–4 0 0 0 0 0 0 
5–9 1 0 0 0 0 0 
10–14 0 0 0 0 0 0 
15–19 3 4 2 2 0 0 
20–24 30 20 14 11 0 1 
25–29 122 124 56 55 7 5 
30–34 237 202 127 87 10 8 
35–39 316 216 150 126 17 13 
40–44 311 221 137 113 12 14 
45–49 291 235 100 110 12 13 
50–54 198 184 89 76 9 8 
55–59 168 130 75 68 10 7 
60–64 178 142 86 72 6 9 
65–69 203 131 83 68 9 2 
70–74 171 147 74 53 7 2 
75–79 137 120 70 51 6 1 
80–84 95 105 44 42 3 0 
85+ 83 65 24 32 1 2 
All ages 
0–85+ years 2,543 2,046 1,131 965 109 85 
Target age 
20–69 years 2,053 1,606 917 785 92 79 
Note: The numbers are presented as 4-year rolling blocks of data. 
Source: National Cancer Statistics Clearing House (AIHW). 
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Table 19: Age-specific and age-standardised incidence rates for cervical cancer by age and location, 
1994–1997 and 1998–2001 
 Major cities  Regional  Remote 
Age group 1994–1997 1998–2001 1994–1997 1998–2001 1994–1997 1998–2001 
0–4 0.0 0.0 0.0 0.0 0.0 0.0 
5–9 0.1 0.0 0.0 0.0 0.0 0.0 
10–14 0.0 0.0 0.0 0.0 0.0 0.0 
15–19 0.2 0.2 0.3 0.3 0.0 0.0 
20–24 1.5 1.1 2.1 1.7 0.0 1.6 
25–29 6.2 6.0 7.5 7.4 7.8 6.5 
30–34 12.1 10.2 14.8 10.8 12.0 9.8 
35–39 16.6 10.7 16.6 13.6 21.5 15.8 
40–44 17.3 11.6 16.5 12.4 18.9 19.9 
45–49 17.2 13.2 13.3 13.3 22.1 22.4 
50–54 15.1 11.2 14.7 10.0 20.9 14.6 
55–59 15.9 10.7 14.4 11.2 29.3 18.4 
60–64 19.1 14.1 18.0 13.6 24.0 29.3 
65–69 21.8 14.6 17.8 14.5 39.0 8.8 
70–74 19.7 16.7 18.0 12.1 41.4 13.7 
75–79 21.2 15.8 23.0 14.2 45.6 7.6 
80–84 20.1 20.6 20.3 17.6 38.3 0.3 
85+ 21.9 14.0 14.5 15.2 10.4 24.8 
All ages 0–85+ years      
AS rate (A) 10.6 7.9 10.2 8.0 14.8 10.1 
95% CI 10.1–11.0 7.5–8.2 9.6–10.8 7.5–8.6 12.0–18.0 8.0–12.5 
AS rate (W) 8.9 6.6 8.7 6.9 12.2 8.7 
95% CI 8.5–9.2 6.3–6.9 8.1–9.2 6.4–7.3 10.0–14.7 6.9–10.8 
Target age 20–69 years      
AS rate (A) 13.7 10.0 13.2 10.6 18.0 14.3 
95% CI 13.1–14.3 9.5–10.5 12.4–14.1 9.9–11.4 14.4–22.1 11.3–17.9 
AS rate (W) 13.0 9.5 12.7 10.2 16.9 13.6 
95% CI 12.4–13.5 9.0–10.0 11.8–13.5 9.5–10.9 13.5–20.7 10.7–16.9 
Notes 
1. The numbers are presented as 4-year rolling blocks of data. 
2. Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population (A) and the WHO World Standard  
Population (W). 
Source: National Cancer Statistics Clearing House (AIHW). 
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Indicator 6.1: Mortality 
Table 20: Deaths from cervical cancer by age, Australia, 1983–2003 
Age group ’83 ’84 ’85 ’86 ’87 ’88 ’89 ’90 ’91 ’92 ’93 ’94 ’95 ’96 ’97 ’98 ’99 ’00 ’01 ’02 ’03
0–4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
15–19 0 0 0 0 0 0 1 1 0 0 0 0 1 0 0 0 0 0 0 0 0
20–24 1 0 0 2 2 0 1 1 3 0 0 0 0 1 0 3 1 1 0 2 0
25–29 8 10 6 6 5 3 3 10 5 5 2 6 3 1 2 6 2 4 1 2 5
30–34 12 13 20 12 15 12 21 14 13 15 11 11 7 13 8 5 6 10 11 6 13
35–39 18 19 17 16 20 15 18 30 25 19 25 11 16 23 18 19 7 12 12 9 12
40–44 20 20 18 26 20 24 24 36 19 27 32 28 21 20 16 19 18 14 19 13 12
45–49 28 26 21 24 19 27 31 36 29 26 23 35 32 30 28 16 25 27 23 15 22
50–54 26 25 25 25 24 19 27 17 21 13 29 37 26 13 21 24 15 19 21 32 17
55–59 40 21 31 41 32 41 20 25 25 23 20 26 34 22 24 15 14 19 20 15 19
60–64 36 41 41 41 28 41 33 34 33 31 25 24 30 21 22 28 15 24 25 19 21
65–69 49 43 52 50 46 41 54 43 35 25 30 37 37 29 30 19 21 26 20 18 20
70–74 30 33 43 32 55 34 48 25 37 45 38 33 43 41 36 28 30 37 28 18 23
75–79 20 29 29 23 29 35 29 32 30 32 28 30 30 38 32 26 26 25 30 26 29
80–84 22 26 26 23 20 34 24 8 22 35 24 26 27 22 27 26 19 23 28 26 21
85+ 21 21 29 24 16 17 22 25 32 23 24 24 20 24 30 31 21 26 24 26 24
All ages 
0–85+ years 330 327 359 343 329 343 355 337 329 319 311 329 328 296 294 265 220 267 262 227 238
Target age 
20–69 years 238 218 230 242 210 222 231 246 208 184 197 216 207 172 169 154 124 156 152 131 141
Note: Deaths were derived by year of registration.  
Source: AIHW Mortality Database. 
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Table 21: Age-specific and age-standardised death rates for cervical cancer by age, Australia,  
1983–2003 
Age group ’83 ’84 ’85 ’86 ’87 ’88 ’89 ’90 ’91 ’92 ’93 ’94 ’95 ’96 ’97 ’98 ’99 ’00 ’01 ’02 ’03
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
20–24 0.1 0.0 0.0 0.3 0.3 0.0 0.1 0.1 0.4 0.0 0.0 0.0 0.0 0.1 0.0 0.5 0.2 0.2 0.0 0.3 0.0
25–29 1.2 1.5 0.9 0.9 0.7 0.4 0.4 1.4 0.7 0.7 0.3 0.9 0.4 0.1 0.3 0.8 0.3 0.6 0.1 0.3 0.7
30–34 1.9 2.1 3.1 1.9 2.3 1.8 3.0 2.0 1.8 2.0 1.5 1.5 0.9 1.8 1.1 0.7 0.8 1.4 1.5 0.8 1.7
35–39 3.2 3.2 2.8 2.5 3.1 2.3 2.7 4.6 3.7 2.7 3.6 1.5 2.2 3.1 2.4 2.5 0.9 1.6 1.6 1.2 1.6
40–44 4.5 4.3 3.7 5.4 3.7 4.1 3.9 5.9 2.9 4.3 5.0 4.3 3.1 2.9 2.3 2.7 2.5 1.9 2.6 1.7 1.6
45–49 7.6 6.9 5.2 5.7 4.4 6.3 6.9 7.6 5.8 4.9 3.9 5.9 5.2 4.7 4.4 2.4 3.8 4.0 3.4 2.2 3.1
50–54 7.2 7.0 7.1 6.8 6.4 4.9 7.1 4.2 5.0 3.0 6.8 8.2 5.6 2.6 3.9 4.2 2.5 3.0 3.2 4.9 2.6
55–59 10.7 5.5 8.4 11.1 8.8 11.3 5.4 6.8 7.1 6.2 5.2 6.9 8.7 5.3 5.7 3.5 3.1 4.0 4.0 2.8 3.3
60–64 10.6 11.5 11.3 11.2 7.7 11.1 9.0 9.3 9.0 8.6 7.1 6.6 8.5 5.8 6.0 7.5 3.9 6.0 6.1 4.5 4.9
65–69 16.8 14.9 17.8 16.4 14.6 12.5 15.7 12.4 10.0 7.2 8.5 10.5 10.5 8.3 8.5 5.4 6.1 7.5 5.8 5.1 5.5
70–74 12.5 13.2 16.6 12.3 20.5 12.8 18.1 9.4 13.2 15.4 12.6 10.5 13.4 12.6 11.0 8.5 9.0 11.1 8.4 5.4 7.0
75–79 11.6 16.7 16.0 11.8 14.8 17.1 13.7 14.7 13.5 14.1 12.4 13.3 13.0 15.7 12.5 9.7 9.3 8.7 10.3 8.8 9.7
80–84 19.9 23.4 22.9 19.0 15.8 26.6 17.6 5.6 14.8 23.3 14.9 15.8 15.9 12.2 15.0 14.3 10.4 12.1 13.9 12.3 9.5
85+ 25.6 24.7 33.1 24.9 16.1 16.7 20.9 23.2 29.4 19.5 19.3 18.4 14.6 16.6 20.1 19.8 12.6 14.8 13.1 13.6 12.2
All ages 0–85+ years        
AS rate (A) 4.9 4.7 5.0 4.7 4.4 4.5 4.5 4.2 4.0 3.8 3.6 3.8 3.7 3.2 3.1 2.7 2.2 2.6 2.5 2.1 2.2
AS rate (W) 3.8 3.6 3.8 3.7 3.4 3.4 3.5 3.3 3.1 2.8 2.8 2.9 2.8 2.4 2.3 2.1 1.7 2.0 1.9 1.6 1.7
Target age 20–69 years        
AS rate (A) 5.4 4.9 5.0 5.2 4.4 4.6 4.6 4.8 4.0 3.5 3.8 4.1 3.8 3.0 3.0 2.7 2.1 2.6 2.5 2.1 2.2
AS rate (W) 5.0 4.5 4.6 4.8 4.1 4.2 4.3 4.5 3.8 3.3 3.4 3.7 3.5 2.8 2.7 2.5 1.9 2.4 2.3 1.9 2.0
Notes: Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population (A) and the WHO World Standard  
Population (W).  
Source: AIHW Mortality Database. 
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Table 22: Deaths from cervical cancer by age, states and territories, 1996–1999 
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0
15–19 0 0 0 0 0 0 0 0 0
20–24 1 2 2 0 0 0 0 0 5
25–29 0 3 4 2 1 0 1 0 11
30–34 7 8 7 8 1 1 0 0 32
35–39 27 13 11 7 4 3 0 2 67
40–44 30 16 14 6 0 1 4 2 73
45–49 40 19 14 10 8 3 3 3 100
50–54 29 12 16 6 3 3 3 1 73
55–59 26 12 17 9 6 3 1 1 75
60–64 27 19 18 6 5 10 0 1 86
65–69 37 20 15 14 7 2 4 1 100
70–74 47 38 22 12 12 2 1 2 136
75–75 43 28 29 6 9 6 0 2 123
80–84 31 35 13 8 5 2 0 0 94
85+ 41 19 14 18 9 3 2 0 106
All ages 
0–85+ years 386 244 196 112 70 39 19 15 1,081
Target age 
20–69 years 224 124 118 68 35 26 16 11 622
Notes 
1. Numbers were averaged over 4 years to smooth annual variations that may occur in the smaller states and territories.  
2. Deaths were derived by year and state of registration. 
Source: AIHW Mortality Database. 
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Table 23: Age-specific and age-standardised death rates for cervical cancer by age, states and 
territories, 1996–1999 
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
20–24 0.1 0.3 0.4 0.0 0.0 0.0 0.0 0.0 0.2
25–29 0.0 0.4 0.7 0.7 0.5 0.0 1.9 0.0 0.4
30–34 0.7 1.1 1.4 2.9 0.5 1.5 0.0 0.0 1.1
35–39 2.7 1.8 2.0 2.4 1.7 3.9 0.0 6.3 2.2
40–44 3.2 2.3 2.8 2.1 0.0 1.4 8.0 7.2 2.6
45–49 4.6 2.9 2.9 3.9 3.8 4.5 6.1 12.8 3.8
50–54 3.9 2.2 3.9 2.9 1.6 5.3 7.7 5.8 3.3
55–59 4.4 2.8 5.5 5.6 4.2 6.6 3.9 9.4 4.4
60–64 5.2 5.0 7.1 4.5 3.9 25.2 0.0 15.0 5.8
65–69 7.4 5.5 6.3 11.6 5.6 5.3 25.3 22.0 7.1
70–74 10.0 11.0 10.0 11.2 9.7 5.6 6.9 63.4 10.3
75–75 11.4 10.3 16.5 7.1 8.9 20.6 0.0 96.0 11.7
80–84 12.0 18.8 10.8 13.5 7.2 9.7 0.0 0.0 13.0
85+ 19.0 11.6 14.0 34.4 15.0 18.4 38.9 0.0 17.3
All ages 0–85+ years    
AS rate (A) 2.9 2.5 3.0 3.2 2.0 3.9 3.5 8.9 2.8
95% CI 2.6–3.2 2.2–2.8 2.6–3.4 2.7–3.9 1.6–2.6 2.8–5.4 2.1–5.6 4.2–15.7 2.7–3.0
AS rate (W) 2.2 1.8 2.3 2.4 1.5 3.1 2.8 6.5 2.1
95% CI 2.0–2.4 1.6–2.1 2.0–2.6 2.0–2.9 1.2–1.9 2.2–4.2 1.7–4.4 3.3–11.2 2.0–2.3
Target age 20–69 years    
AS rate (A) 2.8 2.1 2.9 3.1 1.8 4.4 4.4 6.7 2.7
95% CI 2.5–3.2 1.8–2.5 2.4–3.4 2.4–3.9 1.3–2.5 2.9–6.4 2.5–7.2 3.0–12.4 2.5–2.9
AS rate (W) 2.6 2.0 2.7 2.9 1.7 4.1 4.0 6.1 2.5
95% CI 2.3–3.0 1.6–2.4 2.2–3.2 2.3–3.7 1.2–2.3 2.6–5.9 2.2–6.5 2.8–11.3 2.3–2.7
Notes  
1. The age-standardised rates were averaged over 4 years to smooth annual variations that may occur in the smaller states and territories.  
2. Deaths were derived by year and state of registration. 
3. Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population (A) and the WHO World Standard  
Population (W).  
Source: AIHW Mortality Database. 
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Table 24: Deaths from cervical cancer by age, states and territories, 2000–2003 
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0 0 0 0 0 0 0 0 0 
5–9 0 0 0 0 0 0 0 0 0 
10–14 0 0 0 0 0 0 0 0 0 
15–19 0 0 0 0 0 0 0 0 0 
20–24 3 0 0 0 0 0 0 0 3 
25–29 1 2 2 3 1 1 1 1 12 
30–34 10 4 11 10 2 1 2 0 40 
35–39 13 12 10 2 3 2 2 1 45 
40–44 18 11 16 4 5 2 1 1 58 
45–49 26 16 17 9 14 3 1 1 87 
50–54 34 16 12 10 10 4 0 3 89 
55–59 27 15 14 6 5 4 1 1 73 
60–64 36 16 20 8 7 1 1 0 89 
65–69 27 15 16 13 8 3 1 1 84 
70–74 35 25 23 15 4 4 0 0 106 
75–79 31 33 21 10 9 3 3 0 110 
80–84 32 23 17 16 6 3 0 1 98 
85+ 33 24 15 12 12 4 0 0 100 
All ages 
0–85+ years 326 212 194 118 86 35 13 10 994 
Target age 
20–69 years 195 107 118 65 55 21 10 9 580 
Notes 
1. Numbers were averaged over 4 years to smooth annual variations that may occur in the smaller states and territories.  
2. Deaths were derived by year and state of registration. 
Source: AIHW Mortality Database. 
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Table 25: Age-specific and age-standardised death rates for cervical cancer by age, states and 
territories, 2000–2003 
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
20–24 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1
25–29 0.1 0.3 0.4 1.1 0.5 1.7 1.9 2.8 0.4
30–34 1.0 0.5 2.0 3.5 0.9 1.5 3.9 0.0 1.3
35–39 1.3 1.6 1.8 0.7 1.3 2.9 3.9 3.1 1.5
40–44 1.8 1.5 2.8 1.3 2.1 2.7 1.9 3.4 1.9
45–49 2.8 2.4 3.3 3.2 6.4 4.4 2.0 3.8 3.2
50–54 4.0 2.5 2.5 3.9 4.7 6.2 0.0 13.7 3.5
55–59 3.9 2.9 3.5 3.1 2.9 7.4 3.0 7.0 3.5
60–64 6.4 3.8 6.6 5.2 5.1 2.2 4.4 0.0 5.4
65–69 5.5 4.1 6.5 10.2 6.6 8.0 5.7 18.8 5.9
70–74 7.4 7.3 10.1 13.2 3.3 11.4 0.0 0.0 8.0
75–75 7.4 10.8 10.6 10.4 8.1 9.7 22.4 0.0 9.4
80–84 10.9 10.9 12.1 23.8 7.6 13.3 0.0 60.6 11.9
85+ 12.6 12.3 12.2 18.7 16.7 20.1 0.0 0.0 13.4
All ages 0–85+ years    
AS rate (A) 2.3 2.0 2.6 3.1 2.4 3.3 2.2 3.9 2.4
95% CI 2.0–2.5 1.7–2.3 2.2–3.0 2.6–3.7 1.9–3.0 2.3–4.6 1.1–3.7 1.5–7.8 2.2–2.5
AS rate (W) 1.7 1.5 2.0 2.3 1.9 2.5 1.8 3.1 1.8
95% CI 1.5–1.9 1.3–1.7 1.7–2.3 1.9–2.8 1.5–2.3 1.7–3.6 0.9–3.1 1.3–5.8 1.7–1.9
Target age 20–69 years    
AS rate (A) 2.3 1.7 2.5 2.7 2.7 3.4 2.5 4.6 2.3
95% CI 2.0–2.7 1.4–2.1 2.1–3.0 2.1–3.5 2.1–3.6 2.1–5.2 1.2–4.6 1.9–9.0 2.1–2.5
AS rate (W) 2.1 1.6 2.4 2.5 2.5 3.1 2.4 4.2 2.1
95% CI 1.8–2.5 1.3–1.9 2.0–2.8 2.0–3.2 1.9–3.3 1.9–4.8 1.1–4.4 1.8–8.2 2.0–2.3
Notes 
1. The age-standardised rates were averaged over 4 years to smooth annual variations that may occur in the smaller states and territories.  
2. Deaths were derived by year and state of registration. 
3. Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population (A) and the WHO World Standard  
Population (W).  
Source: AIHW Mortality Database. 
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Indicator 6.2: Mortality by location 
Table 26: Deaths from cervical cancer by age and location, 1996–1999 and 2000–2003 
 Major cities  Regional  Remote 
Age group 1996–1999 2000–2003 1996–1999 2000–2003 1996–1999 2000–2003
0–4 0 0 0 0 0 0
5–9 0 0 0 0 0 0
10–14 0 0 0 0 0 0
15–19 0 0 0 0 0 0
20–24 3 1 2 2 0 0
25–29 6 6 4 5 0 1
30–34 20 29 10 7 1 4
35–39 36 27 26 18 2 0
40–44 43 31 26 22 3 5
45–49 62 59 30 26 5 0
50–54 47 58 24 29 1 1
55–59 45 44 26 27 3 1
60–64 52 48 29 39 4 1
65–69 66 52 29 30 5 2
70–74 89 62 41 40 5 2
75–75 76 72 44 33 2 4
80–84 63 65 28 31 2 2
85+ 74 68 30 30 1 2
All ages 
0–85+ years 684 622 348 340 36 26
Target age 
20–69 years 382 355 206 206 25 15
Notes 
1. Deaths were derived from place of usual residence and by year of registration. 
2. The number of deaths is presented as 4-year rolling blocks of data. 
3. There were 6 deaths excluded from these data because the respective postcodes were not able to be matched to the coding used for this 
analysis. 
Source: AIHW Mortality Database. 
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Table 27: Age-specific and age-standardised death rates for cervical cancer by age and location, 
1996–1999 and 2000–2003 
 Major cities  Regional  Remote 
Age group 1996–1999 2000–2003 1996–1999 2000–2003 1996–1999 2000–2003
0–4 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.0 0.0 0.0 0.0 0.0 0.0
20–24 0.2 0.0 0.3 0.4 0.0 0.0
25–29 0.3 0.3 0.5 0.7 0.5 1.2
30–34 1.0 1.4 1.2 0.8 1.6 4.6
35–39 1.8 1.3 2.8 2.0 2.5 0.3
40–44 2.3 1.6 3.0 2.3 5.0 6.3
45–49 3.6 3.2 3.8 3.0 8.9 0.6
50–54 3.2 3.3 3.6 3.6 2.3 2.3
55–59 4.0 3.3 4.7 4.0 8.6 3.2
60–64 5.4 4.5 5.8 6.9 14.9 2.9
65–69 7.2 5.7 6.2 6.2 20.2 8.4
70–74 10.2 7.1 9.6 9.0 29.6 9.5
75–75 10.7 9.2 13.4 8.8 16.1 29.1
80–84 12.9 11.7 12.3 11.7 23.6 25.4
85+ 17.8 13.5 15.7 12.9 18.3 23.0
All ages 0–85+ years  
AS rate (A) 2.7 2.2 2.9 2.6 5.3 3.6
95% CI 2.5–2.9 2.1–2.4 2.6–3.2 2.3–2.8 3.7–7.4 2.3–5.2
AS rate (W) 2.0 1.7 2.2 2.0 4.1 2.6
95% CI 1.9–2.2 1.5–1.8 2.0–2.5 1.8–2.2 2.8–5.7 1.7–3.8
Target age 20–69 years  
AS rate (A) 2.5 2.2 2.8 2.6 5.2 2.7
95% CI 2.3–2.8 1.9–2.4 2.5–3.2 2.2–3.0 3.2–7.6 1.5–4.4
AS rate (W) 2.3 2.0 2.6 2.4 4.8 2.6
95% CI 2.1–2.6 1.8–2.2 2.3–3.0 2.1–2.8 3.0–7.0 1.4–4.2
Notes 
1. The age-standardised rates are presented as 4-year rolling blocks of data.  
2. Deaths were derived from place of usual residence and by year of registration.  
3. Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population (A) and the WHO World Standard  
Population (W). 
Source: AIHW Mortality Database. 
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Indicator 6.3: Mortality by Indigenous status 
Table 28: Number of deaths and age-specific and age-standardised death rates for cervical cancer by 
age and Indigenous status, Queensland, South Australia, Western Australia and Northern 
Territory, 2000–2003 
 Indigenous  Other Australians 
Age group Number Rate Number Rate
0–4 0 0.0 0 0.0
5–9 0 0.0 0 0.0
10–14 0 0.0 0 0.0
15–19 0 0.0 0 0.0
20–24 0 0.0 0 0.0
25–29 0 0.0 7 0.7
30–34 4 8.8 19 1.8
35–39 0 0.0 16 1.5
40–44 6 18.8 20 1.8
45–49 6 24.0 35 3.4
50–54 3 15.6 32 3.4
55–59 1 7.6 25 3.3
60–64 2 19.9 33 5.5
65–69 3 43.7 35 7.1
70–74 4 86.3 38 8.2
75+ 3 48.4 116 12.2
All ages 
0–85+ years 
 
32 
 
376 
AS rate (A)  13.2  2.5
95% CI  8.4–19.5  2.3–2.8
AS rate (W)  10.0  1.9
95% CI  6.6–14.3  1.7–2.1
Target age 
20–69 years 
 
25 
 
222 
AS rate (A)  12.0  2.5
95% CI  7.5–18.0  2.1–2.8
AS rate (W)  10.9  2.3
95% CI  6.9–16.4  2.0–2.6
Notes  
1. Deaths were derived by state and year of registration. 
2. The number of deaths is presented as a 4-year rolling block of data. 
3. Only Queensland, South Australia, Western Australia and the Northern Territory have Indigenous death registration data considered to be 
of a publishable standard.  
Source: AIHW Mortality Database. 
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Appendixes 
Appendix A: Cervical cancer—symptoms, detection 
and treatment 
Cervical cancer affects the cells of the cervix, which is the lower part of the womb or uterus 
as it joins the inner end of the vagina. Like other cancers, cervical cancer is a disease where 
normal cells change, begin to multiply out of control, and form a growth or tumour. The 
cancer may arise from the squamous cells at the transformation zone where the squamous 
cells on the outside of the cervix join the columnar cells in the lining of the cervical canal 
(squamous cell carcinoma) or from the cells in the cervical canal (adenocarcinoma). Over 
two-thirds of cervical cancers are squamous cell carcinomas, which are most easily detected 
on the Pap smear, and about 20% are adenocarcinomas. If not detected early, the tumour can 
invade local tissue and spread (metastasise) to other parts of the body. The main symptoms 
of cervical cancer are unusual bleeding from the vagina, and very rarely an unusual vaginal 
discharge. However, these symptoms are quite common and may not be due to cancer. 
A cervical cancer may take 10 or more years to develop, but before this the cells may show 
pre-cancerous changes. These early changes can be detected by a Pap smear (which is 
described in more detail below), and with early treatment of these abnormalities, cervical 
cancer can be prevented. The most recent classification of these pre-cancerous lesions has 
two levels of severity, low-grade epithelial abnormalities (LGEA) and high-grade epithelial 
abnormalities (HGEA). An earlier classification described various grades of cervical intra-
epithelial neoplasia (CIN). Low-grade abnormalities include minor changes in squamous 
cells and CIN 1, and high-grade abnormalities include CIN 2, CIN 3, squamous carcinoma-
in-situ, adenocarcinoma in situ and invasive carcinoma (squamous or adenocarcinoma).  
The Pap smear is the most common way to detect pre-cancerous changes which rarely cause 
any symptoms. The test involves a doctor or nurse practitioner inserting a speculum into the 
vagina and gently scraping the surface of the cervix. This process collects cells that are 
transferred onto a slide or into a special liquid, which is then sent to a pathology laboratory 
for assessment. Pap smears are provided by general practitioners, gynaecologists, women’s 
health nurses and, in some locations, Indigenous women’s health workers.  
When a Pap smear shows an abnormality, the woman may be advised to have a repeat smear 
if the abnormality is low-grade or she may be advised to have a colposcopy.  With 
colposcopy, a doctor is able to look directly at the cervix under magnification using an 
instrument called a colposcope. Using a special stain the doctor can highlight any suspicious 
area, which may be pre-cancerous or cancerous. The doctor will then take a tissue sample (a 
biopsy) of the suspicious area for further examination by the pathologist. 
Pre-cancerous changes can be easily and effectively treated to prevent the progression to 
cervical cancer. The type of treatment depends on whether the change observed is low or 
high grade, the woman’s age and general health, whether she wants to have children, and 
her preferences.  
There is a range of treatments for pre-cancerous changes, including laser treatment, loop 
excision (LLETZ), cryosurgery (cold coagulation), electrodiathermy, or cone biopsy (either by 
laser or by scalpel). In a small number of instances, a hysterectomy may be necessary. 
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For invasive cancer, a cone biopsy or hysterectomy is generally performed. If the cancer cells 
are detected on the surface of the cervix only, it may be treated by a cone biopsy. If it has 
invaded more deeply into the cervix, a hysterectomy is generally performed. In advanced 
cases, a radical hysterectomy is needed to remove the cervix and uterus along with a margin 
of tissue around the cervix and lymph nodes from the pelvis. Radiotherapy is sometimes 
used as well as surgery, and for more advanced cases it may be used on its own. 
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Appendix B: Data sources and limitations 
All data used in this report are based on calendar years. Data are derived from multiple 
sources and are summarised below. 
Table B1: Cervical cancer screening indicators data sources 
Indicator Description Data source 
1 Participation rate for cervical cancer screening National Cervical Screening Program 
2 Early re-screening National Cervical Screening Program 
3 Low-grade abnormality detection National Cervical Screening Program 
4 High-grade abnormality detection National Cervical Screening Program 
5.1 
 
Incidence of micro-invasive cervical cancer  
National Cancer Statistics Clearing House (ICD10 C53) 
National Cancer Statistics Clearing House 
 
5.2 
 
Incidence of squamous, adenocarcinoma, 
adenosquamous and other cervical cancer (ICD10 C53) 
National Cancer Statistics Clearing House 
 
5.3 Incidence by location (ICD10 C53) National Cancer Statistics Clearing House 
6.1 
 
 
Mortality from cervical cancer 
(ICD9 180 for data up to and including 1996; ICD10 C53 
for data from 1997 onwards) 
AIHW Mortality Database 
 
 
6.2 Mortality by location AIHW Mortality Database 
6.3 Mortality by Indigenous status AIHW Mortality Database 
Population data 
The Australian Bureau of Statistics estimated resident female population has been used to 
calculate incidence and mortality rates. Participation rates were calculated using the average 
of the 2001 and 2002 estimated resident female population (see Appendix D for tables). There 
may be some variation in published participation rates because national rates use estimated 
resident population data in the denominator whereas local data analysis may use Census 
counts. The denominator population used to calculate cervical screening participation rates 
has been adjusted by the estimated proportion of women who have had a hysterectomy by 
age. These data were derived from the 2001 National Health Survey, and are tabulated in 
Appendix D.  
The age-standardised rates in this publication are calculated using the total estimated 2001 
mid-year Australian resident population. Where appropriate, rates are also standardised to 
the WHO World Standard Population for international comparison. Both the Australian 
Standard Population and the WHO World Standard Population are in Appendix D. 
Indigenous mortality data 
Due to the difficulties of Indigenous identification, mortality data used in Indicator 10 are 
based on deaths in Queensland (for 1998, 1999, 2000, 20001 and 2002), Western Australia, 
South Australia and the Northern Territory only. 
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Other data limitations 
• Hysterectomy fractions are calculated from national data derived from the ABS National 
Health Survey using aggregate data that does not necessarily reflect variation at the state 
or territory level. In this report, data from the 2001 National Health Survey have been 
used.  
• Participation rates will be underestimates to the extent that a small percentage of women 
choose to opt-off local registers and have been excluded from the statistics in this report. 
• The participation numbers for states and territories other than Victoria and the 
Australian Capital Territory and the Australian totals may be overestimated because of 
double counting of some women in registers. This may be the result of difficulty in 
identifying state or territory of residence for women in border areas and the inclusion in 
registers of women resident overseas. 
• Participation rates published by state and territory programs may differ from those in 
this publication because of variation in denominators used.  
• Rates for all ages in incidence and mortality sections are based on data for women aged 
15 years and over. This may have the impact of making incidence and mortality estimates 
for the same year incompatible between publications. 
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Appendix C: Methods 
This appendix describes the methods used to calculate the estimates presented in the tables 
in the body of this publication.  
Crude rates 
A crude rate is defined as the number of events over a specified period of time (e.g. a year) 
divided by the total population. For example, a crude cancer incidence rate is defined as the 
number of new cases of cancer in a specified period of time divided by the population at risk. 
Crude death rates and cancer incidence rates are expressed in this report as rates per 100,000 
population. Crude participation rate is expressed as a percentage. 
Age-specific rates 
Age-specific rates are calculated by dividing the number of cases occurring in each specified 
age group by the corresponding population in the same age group expressed as a percentage 
or a rate per 1,000 or 100,000 population. This rate may be calculated for particular age and 
sex groupings, e.g. 
 
                                      
years 5450 aged population female  2001
2001)(year  years 54–50 aged cases New  
−
=  100,000 ×  
 
           
 648,237
78 =  100,000×    
           100,000per  12.0 =  
Age-standardised rates (AS rate) 
Rates are adjusted for age to facilitate comparisons between populations that have different 
age structures, e.g. between youthful and ageing communities. There are two different 
methods commonly used to adjust for age. In this publication we use direct standardisation 
in which age-specific rates are multiplied by a constant population (the Australian 2001 
Standard Population unless otherwise specified). This effectively removes the influence of 
age structure on the summary rate that is described as the age-standardised rate. The method 
may be used for the calculation of participation, incidence and mortality rates. The method 
used for this calculation comprises three steps:  
Step 1: Calculate the age-specific rate (as shown above) for each age group. 
Step 2: Calculate the expected number of cases in each 5-year age group by multiplying the 
age-specific rates by the corresponding standard population and dividing by 100,000, giving 
the expected number of cases. 
Step 3: Sum the expected number of cases in each age group to give the age-standardised 
rate. Divide this sum by the total of the standard population and multiply by 100,000. 
Age-specific  
cervical cancer 
incidence rate in  
females aged 50–54 
in the year 2000 
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Confidence intervals 
Population numbers for incidence, mortality and screening have a natural level of variability 
for a single year above and below what might be expected in the mean over many years. The 
percentage variability is small for large population numbers but high for small numbers such 
as mortality in a young age group. One measure of the likely difference is the standard error, 
which indicates the extent to which a population number might have varied by chance in 
only one year of data. 
In the 95% confidence interval there are about nineteen chances in twenty that the difference 
will be less than two standard errors. 
The 95% confidence intervals in this report were calculated using a method for obtaining 
approximate confidence intervals for a weighted sum of Poisson parameters developed by 
Dobson et al. (1991). 
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Appendix D: Population data 
Table D1: Australian Standard Population(a) and WHO World Standard Population(b) 
Age group World Standard Population Australian 2001 Standard Population 
0–4 8.86 1,282,357 
5–9 8.69 1,351,664 
10–14 8.60 1,353,177 
15–19 8.47 1,352,745 
20–24 8.22 1,302,412 
25–29 7.93 1,407,081 
30–34 7.61 1,466,615 
35–39 7.15 1,492,204 
40–44 6.59 1,479,257 
45–49 6.04 1,358,594 
50–54 5.37 1,300,777 
55–59 4.55 1,008,799 
60–64 3.72 822,024 
65–69 2.96 682,513 
70–74 2.21 638,380 
75–79 1.52 519,356 
80–84 0.91 330,050 
85+ 0.63 265,235 
Total 100.03 19,413,240 
Sources  
(a) ABS (2002). 
(b) Ahmad et al. 2002. 
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Table D2: Hysterectomy fractions for women aged 15–80+ years,  
Australia, 2001  
Age group % of women who have not had a hysterectomy 
18–19 100.0 
20–24 100.0 
25–29 100.0 
30–34 98.9 
35–39 95.6 
40–44 90.6 
45–49 82.5 
50–54 76.5 
55–59 66.2 
60–64 68.9 
65–69 66.8 
70–74 68.1 
75–79 67.9 
80+ 69.0 
Total  85.5 
Source: ABS 2001 National Health Survey. 
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Table D3: Estimated resident female population, states and territories, June 2000 
Age 
group NSW Vic Qld WA SA Tas ACT  NT  Australia 
0–4 212,248 150,048 119,160 61,978 45,470 15,236 10,327 8,521 623,100 
5–9 220,812 159,285 126,800 65,717 48,675 16,633 10,858 8,396 657,321 
10–14 217,827 157,685 124,667 67,662 49,127 16,792 11,001 7,584 652,475 
15–19 214,103 157,159 126,223 66,450 49,724 16,702 11,844 7,147 649,402 
20–24 211,077 158,650 121,765 63,301 46,456 14,071 12,778 7,714 635,881 
25–29 247,422 184,117 135,753 69,930 51,486 15,541 13,323 9,359 727,009 
30–34 240,000 185,289 131,615 70,453 53,291 16,169 12,582 8,816 718,323 
35–39 255,711 188,110 140,417 74,799 57,901 18,242 12,852 8,251 756,421 
40–44 244,599 180,407 134,766 73,321 57,577 18,175 12,722 7,226 728,900 
45–49 224,723 166,671 124,670 68,226 54,103 16,897 12,337 6,405 674,128 
50–54 207,920 154,790 116,441 60,200 51,550 15,772 11,315 5,088 623,134 
55–59 161,449 117,249 88,394 44,223 39,070 12,350 7,449 3,255 473,483 
60–64 137,200 100,964 70,601 36,564 33,626 10,633 5,336 1,900 396,853 
65–69 121,266 89,014 59,494 30,663 30,036 9,263 4,102 1,235 345,081 
70–74 118,405 86,798 56,363 28,027 30,669 8,777 3,742 853 333,643 
75–79 102,665 74,696 48,012 23,354 27,472 7,758 3,225 560 287,744 
80–84 68,156 48,613 32,106 15,366 18,064 5,345 1,975 369 190,000 
85+ 61,529 46,288 28,770 15,009 16,988 4,673 1,607 286 175,151 
Total 3,267,112 2,405,833 1,786,017 935,243 761,285 239,029 159,375 92,965 9,648,049 
Source: AIHW Population Database based on estimated resident population data compiled by ABS (data extracted March 2005).
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Table D4: Estimated resident female population, states and territories, June 2001 
Age 
group NSW Vic Qld WA SA Tas ACT  NT  Australia 
0–4 213,086 150,321 120,456 61,905 44,962 15,150 10,272 8,594 624,858 
5–9 220,990 159,060 127,970 65,655 48,495 16,360 10,824 8,379 657,874 
10–14 220,821 159,577 127,233 68,044 48,716 16,771 11,073 7,723 660,094 
15–19 218,197 160,653 128,582 68,177 50,536 16,636 12,060 7,173 662,077 
20–24 212,719 160,769 123,091 63,913 46,344 13,999 13,122 7,616 641,636 
25–29 241,462 178,268 132,503 67,908 49,170 14,721 13,030 9,029 706,171 
30–34 248,361 191,148 136,310 72,069 53,575 16,257 12,838 9,047 739,696 
35–39 253,112 187,977 139,855 74,293 56,832 17,524 12,849 8,204 750,770 
40–44 250,299 184,241 138,896 74,398 58,196 18,437 12,815 7,428 744,821 
45–49 227,525 168,515 127,283 69,797 54,391 17,073 12,302 6,543 683,539 
50–54 215,107 160,647 121,798 63,711 53,246 16,338 11,817 5,513 648,237 
55–59 168,272 122,587 93,692 46,062 41,110 12,818 7,906 3,418 495,911 
60–64 140,535 102,654 74,133 37,870 34,124 10,988 5,594 2,111 408,042 
65–69 121,568 89,321 60,179 31,244 29,788 9,248 4,265 1,290 346,923 
70–74 118,705 86,795 57,118 28,484 30,325 8,740 3,731 918 334,826 
75–79 103,805 75,974 48,959 23,787 27,745 7,819 3,320 588 292,000 
80–84 72,230 51,628 34,293 16,288 19,239 5,547 2,159 412 201,800 
85+ 64,220 48,296 30,155 15,998 17,672 4,899 1,765 307 183,313 
Total  3,311,014 2,438,431 1,822,506 949,603 764,466 239,325 161,742 94,293 9,782,588 
Source: AIHW Population Database based on estimated resident population data compiled by ABS (data extracted March 2005). 
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Table D5: Estimated resident female population, states and territories, June 2002 
Age 
group NSW Vic Qld WA SA Tas ACT  NT  Australia 
0–4 209,998 149,393 120,635 61,267 44,412 14,878 10,193 8,471 619,365 
5–9 219,545 158,360 128,718 65,354 47,919 16,064 10,602 8,240 654,942 
10–14 222,365 160,854 130,986 68,209 48,895 16,673 11,090 7,690 666,903 
15–19 219,024 160,582 129,704 68,547 50,462 16,639 11,914 7,129 664,072 
20–24 215,476 164,600 125,384 65,016 47,029 14,105 13,331 7,456 652,455 
25–29 235,186 173,789 129,576 66,068 47,466 13,970 12,776 8,558 687,472 
30–34 254,762 195,255 140,697 73,271 53,979 16,314 13,161 9,154 756,676 
35–39 248,713 186,794 139,540 73,748 55,450 16,992 12,540 8,060 741,963 
40–44 255,317 187,635 143,484 75,781 58,882 18,600 12,938 7,521 760,266 
45–49 230,346 171,093 130,107 70,701 54,719 17,258 12,223 6,522 693,084 
50–54 215,417 160,557 123,151 64,600 52,781 16,242 11,745 5,655 650,212 
55–59 180,476 131,947 102,248 50,183 44,420 13,861 8,727 3,635 535,541 
60–64 143,193 105,156 77,891 39,445 34,713 11,236 5,845 2,325 419,844 
65–69 123,633 91,020 62,742 32,380 30,288 9,446 4,447 1,366 355,344 
70–74 117,855 85,628 57,482 28,694 29,724 8,816 3,725 978 332,914 
75–79 104,309 76,984 49,611 24,224 27,842 7,709 3,401 632 294,715 
80–84 75,377 54,172 36,110 17,269 20,125 5,744 2,266 422 211,487 
85+ 67,203 49,844 31,552 16,378 18,279 5,118 1,891 324 190,591 
Total  3,338,195 2,463,663 1,859,618 961,135 767,385 239,665 162,815 94,138 9,887,846 
Source: AIHW Population Database based on estimated resident population data compiled by ABS (data extracted March 2005). 
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Table D6: Estimated resident female population, states and territories, June 2003 
Age 
group NSW Vic Qld WA SA Tas ACT  NT  Australia 
0–4 207,840 148,831 121,115 60,967 43,903 14,922 10,125 8,487 616,337 
5–9 217,222 157,203 129,778 64,853 47,351 15,733 10,453 8,065 650,780 
10–14 223,122 161,896 134,140 68,675 49,096 16,721 10,871 7,745 672,422 
15–19 218,754 161,148 130,588 69,025 50,340 16,689 11,865 7,059 665,547 
20–24 219,341 168,347 130,226 66,564 47,970 14,287 13,575 7,271 667,642 
25–29 230,834 171,726 129,302 65,248 46,283 13,568 12,654 8,277 677,970 
30–34 258,371 196,664 145,100 73,716 53,573 16,393 13,163 9,120 766,190 
35–39 244,128 186,431 139,805 73,087 54,536 16,690 12,423 7,840 735,055 
40–44 257,199 189,969 147,524 77,038 59,090 18,820 12,884 7,553 770,184 
45–49 234,453 173,918 134,218 71,733 55,317 17,568 12,255 6,632 706,208 
50–54 216,899 161,952 125,720 65,873 53,002 16,594 11,687 5,716 657,524 
55–59 190,744 140,572 110,262 53,925 47,162 14,795 9,351 3,931 570,788 
60–64 145,895 106,921 81,802 40,634 35,363 11,599 6,096 2,482 430,831 
65–69 126,526 93,245 65,471 33,713 30,977 9,703 4,661 1,426 365,745 
70–74 116,043 84,892 57,471 28,824 29,040 8,755 3,725 978 329,740 
75–79 105,559 77,630 50,718 24,825 27,852 7,760 3,424 679 298,451 
80–84 78,343 57,000 37,770 18,292 21,052 5,963 2,428 446 221,296 
85+ 69,395 51,015 32,887 16,706 18,913 5,247 1,979 344 196,489 
Total  3,360,668 2,489,360 1,903,897 973,698 770,820 241,807 163,619 94,051 9,999,199 
Source: AIHW Population Database based on estimated resident population data compiled by ABS  (data extracted March 2005). 
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Table D7: Estimated resident female population, by age and location, for the 4-year periods  
1996–1999 and 2000–2003 
 Major cities  Regional  Remote 
Age group 1996–1999 2000–2003 1996–1999 2000–2003 1996–1999 2000–2003
0–4 1,600,570 1,606,087 824,918 793,326 89,390 84,247
5–9 1,606,581 1,649,313 885,651 884,749 89,223 86,855
10–14 1,596,985 1,658,368 893,325 916,183 77,281 77,343
15–19 1,678,788 1,753,798 775,110 827,419 57,360 59,881
20–24 1,922,307 1,895,396 661,594 640,676 67,481 61,541
25–29 2,055,676 2,010,103 759,837 711,458 84,078 77,061
30–34 1,955,620 2,077,219 822,632 822,289 81,993 81,376
35–39 1,974,730 2,009,408 927,544 897,512 80,042 77,290
40–44 1,849,136 1,987,819 871,176 944,486 66,886 71,866
45–49 1,751,752 1,833,881 791,804 861,567 57,652 61,511
50–54 1,476,475 1,721,713 680,898 802,645 47,727 54,749
55–59 1,118,638 1,353,429 560,272 679,897 35,920 42,397
60–64 953,963 1,056,965 495,444 567,183 27,575 31,422
65–69 912,717 905,959 466,860 483,282 22,551 23,852
70–74 879,096 868,785 423,677 443,404 17,275 18,934
75–75 707,131 783,671 329,975 375,007 12,828 14,232
80–84 486,345 553,842 226,538 260,965 8,692 9,776
85+ 417,569 504,233 188,248 232,742 7,990 8,570
Total 24,944,079 26,229,990 11,585,503 12,144,790 931,946 942,901
Source: AIHW Population Database based on estimated resident population data compiled by ABS (data extracted March 2005). 
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Table D8: Estimated resident Indigenous and other Australian female populations for Queensland, 
Western Australia, South Australia and the Northern Territory, for the 4-year period 2000–2003  
Age group Indigenous Other Australians 
0–4 70,550 869,753 
5–9 70,770 929,595 
10–14 65,439 950,753 
15–19 56,374 960,492 
20–24 48,140 928,976 
25–29 47,744 978,172 
30–34 45,516 1,048,270 
35–39 38,926 1,073,692 
40–44 31,897 1,096,784 
45–49 24,960 1,016,407 
50–54 19,193 954,852 
55–59 13,097 761,893 
60–64 10,072 595,512 
65–69 6,860 495,432 
70–74 4,634 461,314 
75+ 6,201 948,850 
Total 560,373 14,070,747 
Note: Only Queensland, South Australia, Western Australia and the Northern Territory have Indigenous death registration data considered to be of 
a publishable standard. For the purposes of this publication the Indigenous population used as the denominator in calculating mortality rates is the 
total of these four jurisdictions only. The other Australian population is the total population of the same jurisdictions minus the Indigenous 
population. 
Source: AIHW Population Database based on estimated resident population data compiled by ABS (data extracted March 2005). 
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Appendix E: National Cervical Screening Programs 
contact list 
New South Wales 
Ms Jayne Ross 
Program Manager  
NSW Cervical Screening Program 
PO Box 533 
WENTWORTHVILLE  NSW  2145 
Phone: +61 2 9845 8046 
Fax: +61 2 9845 8047 
Email: jayne_ross@wsahs.nsw.gov.au 
Home page: www.csp.nsw.gov.au 
 
Western Australia 
Ms Nerida Steel 
Program Manager 
Cervical Cancer Prevention Program 
1st Floor, Eastpoint Plaza 
233 Adelaide Terrace 
PERTH  WA  6000 
Phone: +61 8 9237 6920 
Fax:  +61 8 9237 6991 
Email: nerida.steel@health.wa.gov.au 
Victoria  
Dr Heather Mitchell  
Medical Director  
Victorian Cervical Cytology Registry 
Email: hmitchel@vcs.org.au 
 
Dr Rosemary Lester 
Dept of Human Services 
Level 17, 120 Spencer Street 
MELBOURNE  Vic  3000 
Phone: +61 03 9637 4130 
Fax:  +61 3 9637 4653 
Email: rosemary.lester@dhs.vic.gov.au 
Home page: www.dhs.vic.org.au 
 
Tasmania 
Ms Gail Raw 
Program Manager 
Dept of Health & Human Services 
GPO Box 125B 
HOBART  Tas  7001 
 
Mr Paul Chandler 
Data Manager 
Phone: +61 3 6230 7753 
Email: paul.chandler@dchs.tas.gov.au 
Home page: www.dchs.tas.gov.au 
 
Queensland 
Ms Jennifer Muller 
Director 
Cancer Screening Services 
Queensland Health 
PO Box 48 
BRISBANE Qld  4001 
Phone: +61 7 3234 0905 
Fax: +61 7 3235 2629 
Email: jennifer_muller@health.qld.gov.au 
South Australia 
Ms Penny Isofidis 
Acting Program Manager  
SA Cervical Screening Program 
2nd Floor, Norwich Centre 
55 King William Road 
NORTH ADELAIDE  SA 5006 
Phone: +61 8 8226 8182 
Fax: +61 8 8226 8190 
Email: penny.isofidis@health.sa.gov.au 
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Australian Capital Territory 
Ms Helen Sutherland 
Program Manager 
ACT Health 
GPO Box 825 
CANBERRA  ACT  2601 
Phone: +61 2 6205 1540 
Fax: +61 2 6205 1394 
Email: helen.sutherland@act.gov.au 
 
Mr Peter Couvee 
Database Manager/Coordinator 
ACT Cervical Cytology Register 
ACT Community Health 
GPO Box 825 
Canberra  ACT  2601 
Phone: +61 2 6205 1955 
Fax: +61 2 6205 5035 
Email: peter.couvee@act.gov.au  
 
 
Northern Territory 
Ms Vera McMahon 
Program Coordinator 
Well Women’s Cancer Prevention Program 
Territory Health Services 
PO Box 40596 
CASUARINA  NT  0810 
Phone: +61 8 8922 6445 
Fax: +61 8 8922 5511 
Email: vera.mcmahon@nt.gov.au 
 
Mr Guillermo Enciso 
Data Manager 
Casuarina Health Services Centre 
Territory Health Services 
PO Box 40596 
CASUARINA  NT  0810 
Phone: +61 8 8922 6441 
Fax: +61 8 8922 6447 or 6455 
Email: guillermo.enciso@nt.gov.au 
 
Australian Government Department of Health and Ageing 
Population Screening Section 
Department of Health and Ageing 
GPO Box 9848 
CANBERRA  ACT  2601 
Phone: +61 2 6289 8302 
Fax: 61 2 6289 4021 
Home page:  www.cervicalscreen.health.gov.au 
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Appendix F: NHMRC guidelines for the management of women with screen-
detected abnormalities (under review) 
This reference sheet is a summary of the NHMRC guidelines (1994) for the management of women with screen-detected abnormalities. It is intended 
to help medical practitioners take appropriate action on receipt of Pap smear reports. 
Low-grade epithelial abnormalities 
Pap smear report Investigation Management 
Non-specific minor squamous cell 
changes/atypia 
 Repeat smear at 12-monthly intervals until it reverts to normal. 
Minor changes in endocervical cells/low-grade 
glandular change 
Repeat smear in 6 months using cytobrush and spatula. If low-
grade abnormality persists, refer for colposcopy and biopsy if 
indicated. 
If endocervical cell abnormality confirmed, refer to gynaecologist for 
appropriate treatment. 
HPV effect/HPV-associated cell changes Repeat smear at 6-monthly intervals. If HPV-associated cell 
changes persist after 12 months, refer for colposcopy. 
If HPV confirmed, continue with 6-monthly smears until 2 negative 
reports are received. Repeat smear annually for 2 years then revert 
to 2-yearly screening. 
Possible CIN 1 ± HPV/possible mild dysplasia Repeat smear at 6-monthly intervals until 2 successive negative 
reports are received. If lesion persists for 12 months, refer for 
colposcopy. 
If CIN 1 confirmed, follow either observational or active 
management program as explained on next page. 
CIN 1 ± HPV/mild dysplasia Refer for colposcopy and biopsy if indicated. If CIN 1 confirmed, follow either observational or active 
management program as explained on next page. If higher grade 
abnormality diagnosed, see below. 
 
High-grade epithelial abnormalities 
Pap smear report Investigation Management 
CIN 2 ± HPV/moderate dysplasia Refer for colposcopy and directed biopsy. If CIN 2 confirmed, treatment by gynaecologist with appropriate 
expertise is required. 
CIN 3 ± HPV/severe dysplasia Refer for colposcopy and directed biopsy. If CIN 3 confirmed, treatment by gynaecologist with appropriate 
expertise is required. 
CIN 3 ± HPV with possible invasion; 
endocervical glandular dysplasia; or 
adenocarcinoma in situ 
Refer to gynaecologist with expertise in colposcopic evaluation of 
malignancies. 
Treatment by gynaecologist with appropriate expertise is required. 
Invasive squamous cell carcinoma (SCC) or 
Adenocarcinoma 
Refer to gynaecologist skilled in the management of malignancies, 
or a specialist unit, for urgent evaluation and management. 
Treatment by gynaecologist with appropriate expertise is required. 
Inconclusive—abnormal cells highly suggestive 
but not diagnostic of a high-grade abnormality 
Refer for colposcopy and possible biopsy, unless there is an 
obvious diagnostic difficulty, e.g. epithelial atrophy or infection. In 
this case, treat the problem and repeat the smear. 
If high-grade lesion confirmed, treatment by gynaecologist with 
appropriate expertise is required. 
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Management of women with low-grade epithelial abnormalities 
A cytological assessment of CIN 1 requires referral for colposcopy and, if indicated, biopsy. There is controversy over the management—observational and active. Both treatment 
options should be fully discussed with the woman. 
Observational management 
If the diagnosis of CIN 1 is confirmed and the woman elects not to be treated, cervical smears should be taken at 6-monthly intervals until the abnormality either regresses or 
progresses. After 2 negative smears at 6-monthly intervals, smears should be taken at yearly intervals. If two consecutive annual smears are normal, the woman can revert to 2-yearly 
screening. 
Active management 
Treatment by an accepted method, either ablative or excisional. 
 
Pap smear report Management 
Negative/within normal limits Repeat smear in 2 years. 
Negative/within normal limits and no endocervical cells 
present 
Repeat smear in 2 years. 
Negative with inflammation Repeat smear in 2 years. 
Note: Investigate any symptoms that are not readily explained, such as post-coital or intermenstrual bleeding. A negative Pap smear must not be taken as reassurance in these 
circumstances. Further investigation may involve referral to a gynaecologist. 
Unsatisfactory Repeat smear in 6–12 weeks, with treatment and where possible correction of any problems beforehand if appropriate. 
 
Post-treatment assessment 
After initial post-treatment colposcopic assessment by gynaecologist, repeat smear at 6-monthly intervals for 1 year. 
Following treatment of a high-grade epithelial abnormality, smears should be repeated yearly thereafter. Following 
treatment for a low-grade epithelial abnormality, revert to normal 2-yearly screening after 2 consecutive normal smears at 
yearly intervals.  
Special circumstances  
Total hysterectomy for CIN Annual smears from vaginal vault for 5 years, then revert to 2-yearly smears. 
Total hysterectomy for benign causes No further smears required if previous smears were negative. Baseline smear if reason for hysterectomy and/or previous 
Pap smear history unknown. 
Subtotal hysterectomy for benign causes—cervix 
present 
Continue normal 2-yearly screening. 
Abnormality during pregnancy Refer for colposcopy during 1st trimester to exclude invasive disease. If confirmed high-grade abnormality, repeat 
colposcopy during mid-trimester to exclude progression. Lesion should be reassessed 8 weeks post-partum. 
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Glossary  
Ablative therapy: the destruction of cells on the surface of the cervix using laser therapy, 
chemicals or diathermy. 
Adenosquamous: a mix of adenocarcinoma and squamous cells in the same sample. 
Adenocarcinoma: a cancer formed from the cells of a gland. 
Adjuvant: enhancing or administered to enhance the effectiveness of a treatment or 
substance. 
AS rate: age-standardised rate 
Atypia: the condition of being irregular. 
Basement membrane: the delicate, non-cellular layer on which an epithelium is seated. The 
epithelium forms the surface portion of the skin and lines hollow organs and all passages of 
the respiratory, digestive and genito-urinary systems. 
Benign: not malignant. 
Cancer (malignant neoplasm): a term used to describe one of several diseases which result 
when the process of cell division, by which tissues normally grow and renew themselves, 
becomes uncontrolled and leads to the development of malignant cells. These cancer cells 
multiply in an uncoordinated way, independently of normal growth control mechanisms, to 
form a tumour. This tumour may expand locally by invasion or systemically by metastasis 
via the lymphatic or vascular systems. If left untreated, most malignant tumours will 
eventually result in death. 
Cancer death: a death where the underlying cause is indicated as cancer. Persons with cancer 
who die of other causes are not counted in the death statistics in this publication. 
CIN (cervical intraepithelial neoplasia): squamous cell carcinoma of the cervix is mostly 
preceded, over a period of years, by a spectrum of asymptomatic abnormalities known as 
cervical intraepithelial neoplasia (CIN) graded as CIN I (mild dysplasia), CIN II (moderate 
dysplasia) and CIN III (severe dysplasia and carcinoma-in-situ). CIN usually occurs at least a 
decade before cervical cancer. If CIN remains untreated, some women will develop cervical 
cancer and others will progress to invasive cervical cancer, despite treatment (AIHW: Jelfs 
1995). 
Cone biopsy: biopsy in which an inverted cone of tissue is excised, as from the uterine 
cervix. 
Colposcopy: an examination of the lower genital tract with a magnifying instrument called a 
colposcope. This method of conservative evaluation allows the clinician to more accurately 
assess the cytologic abnormality by focusing on the areas of greatest cellular abnormality and 
by sampling them with a punch biopsy to attain diagnosis. 
Cryosurgery: the destruction of tissue using extreme cold. 
Dysplasia: abnormal cell growth. 
Endocervical: the inside of the uterine cervix or the mucous membrane lining of the cervix.  
Epidemiology: the quantitative study of the distribution and determinants of health-related 
states and events in populations, and the application of this study to the control of health 
problems. 
 88 
 
Epithelium: the covering of internal and external surfaces of the body, including the lining of 
vessels and other small cavities. It consists of cells joined by small amounts of cementing 
substances. It is classified into types on the basis of the number of layers deep and the shape 
of the superficial cells. 
Exfoliate: to break away or remove. 
HGA: high-grade abnormalities as defined for this report include CIN 1/2, CIN 2, CIN 3 or 
adenocarcinoma in situ. 
Histology: the microscopic study of the minute structure and composition of tissues. 
Hysterectomy: refers to the surgical procedure whereby all or part of the uterus is removed. 
Hysterectomy fractions: the proportion of women who have had their uterus removed by 
hysterectomy. 
HPV: Human papilloma virus. 
ICD-10: International Classification of Disease—a coding system used to identify the primary 
site of the malignancy. This classification is in its tenth revision. 
Incidence: see new cancer case 
Intraepithelial: the area within the layer of cell tissues forming the epidermis of a body 
cavity. These cells comprise contiguous cells having minimum intercellular substance. 
Invasive cancer: a tumour whose cells have a tendency to invade healthy or normal tissues. 
LGA: low-grade abnormalities include atypia, warty atypia (human papilloma virus (HPV) 
effect), possible CIN, equivocal CIN, CIN 1 or endocervical dysplasia not otherwise specified. 
Lymph node: masses of lymphatic tissue, often bean-shaped, that produce lymphocytes and 
through which lymph filters. These are located throughout the body. 
Malignant: abnormal changes consistent with cancer. 
Metastasis: the process by which a disease is transferred from one part of the body to 
another, for example via the lymphatic system or the bloodstream. 
Mortality: see cancer death. 
Neoplasia: the process by which tumours are formed. 
New cancer case: a person who has a new cancer diagnosed for the first time. One person 
may have more than one cancer and therefore may be counted twice in incidence statistics if 
it is decided that the two cancers are not of the same origin. This decision is based on a series 
of principles set out in more detail in a publication by Jensen et al. (1991). 
Pap smear: a test prepared for the study of exfoliated cells from the cervix (refer to  
Appendix A). 
Post-partum: following childbirth. 
Radiation therapy: the treatment of disease with any type of radiation, most commonly with 
ionising radiation, such as X-rays, beta rays and gamma rays. 
Screening: the performance of tests on apparently well people in order to detect a medical 
condition at an earlier stage than would otherwise be the case. 
Sensitivity: the proportion of individuals with the disease whom the screening test labels 
positive. 
Squamous malignancy: cervical cancer can be derived from several cells types. One of these 
cell types is the squamous cell and most cervical cancers are derived from this cell type. 
Stroma: the supporting framework of an organ. 
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